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Clinical oncologists were the first to observe that cancers treated with multiple 
different anticancer drugs tended to develop cross-resistance to many other 
cytotoxic agents to which they had never been exposed, effectively eliminating the 
possibility of curing these tumors with chemotherapy. This phenomenon is called 
multidrug resistance (MDR). Multidrug resistance in human tumor cells is often 
associated with enhancement of some members of the ATP-binding cassette (ABC) 
superfamily of transporter proteins. These include multidrug resistance-associated 
protein (MRP), P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). 
MRP proteins have the ability to confer resistance to a broad spectrum of 
chemotherapeutic agents. They also facilitate the ATP-dependent export of 
conjugates with glutathione, glucuronate or sulfate. 
 
Multidrug resistance protein 4 (MRP4/ABCC4) is a member of the MRP family. 
Like other MRPs, MRP4 is organic anion transporter, but it has the unique ability 
to transport cyclic nucleotides and some nucleoside monophosphate analogs as 
PMEA. Moreover, MRP4 has the ability to confer resistance to 6-MP and 6TG, 
thus extend the drug resistance profile beyond the antiviral purine analog PMEA to 
the commonly used anticancer purine analog 6-MP. 
  
To further characterize the function of MRP4, we generated stably transfected 
MRP4/HepG2 cells. As expected, MRP4/HepG2 cells showed a 2.67 fold 
 7
resistance to 6-thioguanine (6TG) and can mediate the export of 
bimane-glutathione conjugate. To screen for compounds which can be used to 
selectively inhibit MRP4, two series of compounds with either the oxopurine or 
azapurine templates were synthesized (by Fu Han and Makam Shantha Kumar 
Raghavendra in Dr Lam Yulin’s Lab, Department of Chemistry, NUS). Four of 
these compounds (FH-15, FH-16, MSR-37, MSR-15) were able to selectively 
inhibit MRP4-meidated bimane-GS transport and also reverse the 6TG resistance. 
Inhibition of bimane-GS transport was achieved at 25-125μM. In addition, the 
presence of 10μM FH-15 and 25μM FH-16, MSR37 and MSR15 were able to 
completely abolish the resistance to 6TG. All four compounds did not affect the 
cell growth and viability. 
 
To gain insight into the role of key amino acid residues of MRP4 protein for 
transport organic anions and resistance to chemotherapeutic compounds, three 
aromatic amino acids Trp216, Trp230, Phe324 were substituted with either 
non-conserved (Ala) or aromatic amino acid (Trp or Phe) in TM 3 and TM 5. The 
constructs were generated using site-directed mutagenesis. All mutated 
MRP4-pcDNA6 constructs were transfected into HepG2 cells. The protein 
expression levels and localization were comparable to that of wild-type MRP4. 
The bimane-GS efflux assays and the cytotoxic assays were then carried out to 
determine to see whether the transport ability of glutathione conjugate and drug 
resistance had changed in these mutants. The data showed that all mutants had lost 
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the ability of transporting bimane-glutathione and resistance to 6TG. In summary, 
our present study suggests that the aromatic amino acid Trp216, Trp230, Phe324 in 
the transmembrane helices of MRP4 play a pivotal role in determining the 
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1.1   Multidrug resistance (MDR) 
Clinical oncologists were the first to observe multidrug resistance (MDR), a 
phenomena whereby cancers treated with multiple different anticancer drugs 
tended to develop cross-resistance to many other cytotoxic agents to which they 
had never been exposed. Inherent or acquired MDR is responsible for limiting the 
effectiveness of many anti-cancer drugs during chemotherapy (Hrycyna et al., 
2001). 
 
There are three major changes in cells that develop MDR: 1) decrease in the 
accumulation of cytotoxic drugs. 2) changes in the activity or expression of some 
proteins such as P-glycoprotein (P-gp), multidrug resistance-associated protein 
(MRP). 3) changes in cellular physiology affecting the structure of the plasma 
membrane, the cytosolic pH, and the rates and extent of intracellular transport of 
membrane (Simon and Schindlert 1994 ). 
 
There are several mechanisms of MDR. The first is ATP-binding cassette (ABC) 
transporter-mediated resistance including P-gp /MDR1-mediated classic MDR; 
MRP family member-mediated MDR; breast cancer resistance protein 
(BCRP)-mediated MDR. The second is lung resistance protein (LRP)-mediated 
MDR, and the third is MDR associated with altered topoisomerases activities 
(Ambudkar et al., 1999). 
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1.2   Metabolism of toxicant 
Lipophilic xenobiotics and endogeneous compounds often have to be metabolized 
before being eliminated from the cell. The metabolism of toxicant consists of three 
phases. The sensitivity or resistance to a specific drug or xenobiotic toxin can be 
influenced by the alteration of these three phases. In phase I metabolism, the 
reactions are catalyzed by cytochrome P450 or flavin mixed-function oxidase and 
the drug or xenobiotic tends to be more electrophilic resulting in a more reactive 
intermediate. This may result in enhanced toxicity. During phase II, phase I 
metabolites or the unmodified drugs in certain cases may then be converted to 
less-reactive, presumably less-toxic products. The phase II metabolism is regarded 
as the detoxification process of xenobiotics. Through conjugation reaction with 
glucuronide, sulfate or glutathione, activated hydrophobic xenobiotics are 
converted into more hydrophilic forms by phase II enzymes. Phase III 
detoxification consists of export of the parent drug/xenobiotic or its metabolites by 
energy-dependent transmembrane efflux pumps, including MRP transporters 
(Cancer Medicine, Section 11, Chemotherapy). The phase I (oxidation), II 
(conjugation) and III (elimination) systems are involved in xenobiotic metabolism 
as well as in the synthesis and metabolism of biologically active endogenous 
substances. 
 
Figure 1.1  Drug detoxification Phases I, II, and III (Adapted from Cancer 












1.3   Glutathione and Glutathione conjugate export pump  
Glutathione is a tripepetide containing a sulfhydryl group (Figure 1.2). It has two 
forms – a reduced thiol form (GSH) and an oxidized form (GSSG) whereby the 
two tripeptides are linked by a disulfide bond. Glutathione cycles between these 
two forms. GSSG is reduced to GSH by glutathione reductase, a flavoprotein that 
uses NADPH as the electron source. 
 
Figure 1.2. Structure of glutathione. This tripeptide consists of a cysteine residue 
flanked by a glycine residue and a glutamate residue that is linked to cysteine by 
an isopeptide bond between glutamate's side-chain carboxylate group and 
cysteine's amino group (Adapted from Biochemistry, Chapter 24, The biosynthesis 
of Amino Acids). 
 
Glutathione conjugation is one of the systems in the detoxification of many 
anticancer drugs. The major components of this system include glutathione (GSH), 
GSH-related enzymes and the glutathione conjugate export pump (GS-X pump). 
GSH is a major cellular anti-oxidant. GSH can combine with anticancer drugs to 
form less toxic and more water soluble glutathione conjugates. The conjugation 
reaction is catalyzed by glutathione S-transferase (GST).  
 R-SG+ HX
 GST 













γ-glutamate Cysteine Glycine 
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The glutathione conjugates of anticancer drugs can be exported from cells by the 
GS-X pump. GSH, glutathione-related enzymes and GS-X pump have been found 
to be increased or overexpressed in many drug resistant cells. Increased 
detoxification of anticancer drugs by this system may confer drug resistance and 
inhibition of this detoxification system is a strategy for modulation of drug 
resistance (Zhang et al., 1996; Klein et al., 1999; Borst et al., 2000).  
 
GSTs are phase II enzymes that catalyze the conjugation of GSH to a variety of 
endogenous and exogenous electrophilic compounds. Evidence suggests that the 
level of expression of GST is a crucial factor in determining the sensitivity of cells 
to a broad spectrum of toxic chemicals (Hayes et al., 1995; Hodgson et al., 1997).  
 
Ishikawa et al proposed that the ATP-dependent GS-X pump is an essential feature 
of Phase III, and this constituted a new concept in drug metabolism and the 
detoxification of xenobiotics. The GS-X pump has been shown to belong to the 
ABC transporter family and it was suggested that it contributes to anticancer drug 
resistance (Ishikawa et al., 1992). In humans, the GS-X pump has now been 
identified as the multidrug resistance-associated protein (MRP, also known as 
MRP1) (Muller et al., 1994; Suzuki et al., 2001). 
 
1.4    ATP-binding cassette (ABC) family 
The ATP-binding cassette (ABC) family is one of the largest superfamilies of 
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proteins (Table 1.1) known in both eukaryotic and prokaryotic organisms. ABC 
proteins transport a wide spectrum of substrate including ions, phospholipids, 
steroids, polysaccharides, amino acids and peptides. In humans, members of this 
family are expressed in many tissues and are involved in a large variety of 
physiologic processes, such as signal transduction, protein secretion, drug and 
antibiotic resistance, as well as antigen presentation (Klein et al., 1999; Janas el al, 
2003).  
 
Proteins which belong to the ABC transporter superfamily have an ATP-binding 
domain (also known as nucleotide binding folds, NBFs) that binds and hydrolyzes 
ATP to provide the energy to transport a number of molecules against steep 
concentration gradients. The ATP binding domain is conserved throughout the 
biological kingdom and contains three motifs, the Walker A and B motifs separated 
by about 100 amino acids plus a signature motif (C-loop motif) whose position can 
vary greatly compared to the other two (Figure1.3 B). In contrast to the NBFs, the 
membrane spanning domains (MSDs) of ABC transporters are highly divergent. 
This sequence divergence is consistent with the notion that the MSDs are 
important determinants of the different substrate specificities of various ABC 
transporters. The functional protein usually consists of two hydrophilic, cytosolic 
ATP-binding domains and two hydrophobic, polytopic MSDs (Figure 1.3 A). Half 
molecules with one MSD and one NBF also exist. The NBFs are located in the 
cytoplasm. Each MSD usually has 6-11 α-helices that span the membrane and 
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provides the specificity for the substrate. The MSDs interact with the substrates 
and form the substrate translocation pore across the membrane (Decottignies and 




Figure 1. 3.  Structure of a typical ABC transporter protein.  
A. The structure of a representative ABC protein is shown with a lipid bilayer, the 
membrane spanning domains (MSD), and the nucleotide binding fold (NBF).  
B. The NBF of an ABC gene contains the Walker A and B motifs found in all 
ATP-binding proteins. In addition, a signature or C motif is also present (adapted 
from Dean et al., 2001). 
 
Table 1.1  List of Human ABC genes, their chromosomal location and tissue 
expression (adapted from Dean et al., 2001). 
                                                        
Subfamily 
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1. 5   P-glycoprotein (P-gp)/MDR1 
The best-studied mechanism of MDR is that due to the overexpression of an 
energy-dependent multidrug efflux pump, known as the multidrug transporter, or 
P-gp. P-gp/ MDR1 was the first member of the ABC transporter superfamily to be 
identified in a eukaryote organism (Fojo et al., 1985; Roninson et al., 1986). 
Human P-gp is encoded by the MDR1 gene and consists of 1280 amino acids. 
P-gp is a 170 kDa broad-spectrum multidrug efflux pump that is composed of two 
homologous halves, each containing six transmembrane helices, followed by a 
hydrophilic domain containing a nucleotide-binding site, separated by a flexible 
linker polypeptide. The amino acid sequence and domain organization of the 
protein is typical of the ABC superfamily of transporters (as shown in Figure 1.3) 
(Endicott et al., 1989; Hyde et al., 1990). 
 
P-gp acts as an energy-dependent pump that extrudes hydrophobic cytotoxic drugs 
such as colchicine, actinomycin D, and the vinca alkaloids, out of the cells 
(Endicott et al., 1989). These drugs enter cells by passive diffusion through the 
plasma membrane. P-gp presumably binds drugs embedded in the membrane, and 
their transport out of the cell is coupled to ATP hydrolysis (Raviv et al., 1990). It 
has been demonstrated that P-gp possesses high levels of ATPase activity that is 
stimulated in the presence of drug substrates (Ambudkar et al., 1992; Sarkadi et al., 
1992; Al-Shawi and Senior, et al., 1993).  
 
 25
P-gp is expressed in normal tissues such as liver, intestines, and kidney. The 
physiological function of P-gp is to transport a variety of natural and metabolic 
toxins into the bile, intestinal lumen or urine, thereby protecting the entire 
organism (Bosch et al., 1996). P-gp is also localized in the endothelial cells of 
capillaries in the brain and serves to prevent the penetration of cytotoxin across the 
endothelium, which forms the blood-brain barrier (Sharom et al., 1998). The 
location of P-gp in the gut epithelium helps to prevent entry of drugs into the body 
(Sparreboom et al., 1997). Its location in renal tubules and in the canalicular 
membrane of the hepatocytes helps to clear drugs from the body, and its presence 
in strategic locations in the brain (Schinkel et al., 1994), the testis, and the placenta 
helps to protect these organs and the fetus against drugs (Lankas et al., 1998). 
 
1.6  Multidrug resistance-associated protein (MRP) 
 
The multidrug resistance-associated protein (MRP) family entered the drug 
resistance scene in 1992 when Susan Cole and Roger Deeley cloned the first MRP 
gene, now known as MRP1 (Cole et al., 1992). To date, this subfamily has 9 
members. MRP2 was identified in 1996 (Buchler et al., 1996). Then, the notion of 
a MRP family with five members was introduced at the Gosau meeting on ABC 
transporters in 1997 by Marcel Kool (Klein et al., 1999). MRP6 was cloned in 
1998 (Kool et al., 1999b) and MRP7 in 2001 (Hopper et al., 2001). Recently, the 
sequences of two more members, MRP8 and MRP9 were described by Tammur et 
al (Tammur et al., 2001). Summaries of what is known about MRP genes and their 
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functions are shown on Table1.2 and 1.3. 
 
Table 1.2  Summary of MRP family members (properties, tissue distribution,  
physiological functions) (Belinsky et al., 1999; Klein et al., 1999; Hopper et al., 
2001). 
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Table 1.3  Transport properties of MRP family members (conjugate transport, 
glutathione transport, resistance profile, notable physiological substrate) (Belinsky 











MRP1 + + Anth,Vinc, Etop 
Camp,MTX 
LTC4 




MRP3 + - Etop, MTX Glycocholic 
acid 





MRP5 - + 6-MP, PMEA Cyclic 
nucleotides 
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MRP6 + ?  Anth, Etop, Plat ? 
MRP7 + ? ? ? 
MRP8 ? ? 5-FU,ddC,PMEA Cyclic 
nucleotides 
MRP9 ? ? ?    ? 
 
Anth = anthracyline;   Vinc = vinca alkaloids;   Etop = etoposide;  
Camp = camptothecine;  MTX = methotrexate;   Plat = cisplatin   
6-MP=6-mercaptopurine; PMEA=9-(2-phosphonylmethylethyl)adenine  
5-FU = 5-Fluorouracil;  ddC = 2’, 3’-dideoxycytidine 
LTC4 = Leukotriene C4   DHEAS= dehydroepiandrosterone 3-sulphate 
 
The MRPs are ABC transporters and belong to the ABCC subfamily. The MRPs 
are divided into two groups based on the degree of amino acid identity and the 
predicted topology of the full-length proteins. One group consists of MPR1,-2,-3 
and -6, -7. These have the characteristic MSD0L0 segment which is also seen in 
GS-X pumps from simple eukaryotes, such as yeast and Leishmania (Ishikawa et 
al., 1997). The other group consists of MRP4, -5,-8,-9 and lacks the MSD0 domain. 
It should be noted that MRP4 and -5 still have the basic structure that is required 
for the GS-X pump activity, i.e. the P-gp-like core structure and the L0 loop (Bakos 









Figure 1.4.  Two-dimensional membrane topology models for MRP1 and MRP5. 
MRP1 is characterized by the presence of an extra N-terminal domain (MSD0) of 
five transmembrane helices, which is absent in P-gp or MRP5 (MSD= membrane 
spanning domain, NBF = nucleotide binding fold, L0 = cytoplasmic linker). Note 
that this figure presents highly schematic models only indicating the 
transmembrane segments and the adenosine triphosphate-binding domains 








1.6.1  MRP1 
MRP1 (ABCC1) is the best characterized MRP protein and its cDNA was first 
isolated from the doxorubincin-selected multidrug resistance lung cancer cell line, 
H69AR in 1992. Human MRP1 maps to chromosome 16p13.11 and the gene 
comprises of 31 exons. The encoded protein consists of 1531 amino acids, and 
when fully glycosylated, has a molecular mass of 190 KDa. MRP1 is expressed in 
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testis, kidney and peripheral blood mononuclear cells (Cole et al., 1992). MRP1 is 
located in the basolateral membranes of polarized epithelial cells rather than apical 
membranes where P-gp, MRP2 are located. 
  
MRP1 has 17 transmembrane (TM) helices and two nucleotide binding domains 
that hydrolyze ATP. The TM regions are divided into three core MSDs, the first 
(MSD0) encodes five TM helices, while the two other (MSD1 and MSD2) each 
contains six TM helices and the two NBDs (NBD1 and NBD2) are located after 
MSD1 and MSD2, respectively. Although a region equivalent to MSD0 does not 
exist in P-gp, the organization of MSD1 and MSD2 are similar to the topology of 
P-gp. A cytoplasmic loop in MRP1 connects MSD0 to the P-gp like core of MSD1 
and MSD2 and is termed linker domains 0 (L0). The predicted topological 
organization of MRP1 from the NH2 terminus to the COOH terminus of the 
protein proceeds as following: MSD0-L0-MSD1-NBD1-L1-MSD2-NBD2 (Bakos et 
al., 1996).  
 
Many of the features of multidrug resistance associated with overexpression of 
MRP1 have been shown to be similar but clearly distinct from those of P-gp 
mediated drug resistance. Like P-gp, MRP1 confer resistance to a wide spectrum 
of drugs including anthracyclines, epipodophyllotoxins and vinca alkaloids. MRP1 
can also transport folic acid analogue such as methotrexate (MTX), and certain 
arsenic and antimonial centered oxyanions (Cole et al., 1994; Hipfner et al., 1997; 
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Loe et al., 1998; Hooijber et al., 1999). 
  
One notable aspect of MRP1-mediated resistance is the involvement of GSH. 
MRP1-mediate transport of some natural product drugs such as vincristine, 
etoposide, doxorubicine and daunorubicin is enhanced in the presence of GSH 
(Loe et al., 1996a; Renes et al., 1999; Mao et al., 2000). MRP1 is also a primary 
active transporter of GSSG, GSH, glucuronate and sulfate conjugated organic 
anions (Leslie et al., 2001a). It has been reported that verapamil, a calcium channel 
blocker, can increase MRP1’s affinity for GSH and this ability to stimulate GSH 
transport is shared by several dithiane analogs of verapamil and several flavonoids 
(Loe et al., 2000; Leslie et al., 2001b). Recent studies have shown that MRP1 can 
transport dehydroepiandrosterone 3-sulphate (DHEAS) in the presence of GSH or 
the non-reducible GSH analogue S-methyl-GSH. DHEAS is synthesized in the 
adrenal gland, and is the most abundant circulating steroid in humans. MRP1 has a 
high expression level in adrenal cortex. This strongly suggests that it is an 
important adrenal DHEAS efflux pump (Zelcer et al., 2003). In addition, two of 
the best characterized substrates of MRP1 are the GSH-conjugated arachidonic 
acid derivative leukotriene C4 (LTC4) and the glucuronidated estrogen, 
17ß-estradiol 17-(ß-D-glucuronide) (E217ßG) (Jedlitschky et al., 1994; Leier et al., 





Long before the discovery of MRP1, biochemical and genetic studies had 
demonstrated the presence of an organic anion transporter in the canalicular 
membrane of hepatocytes. This transporter was originally known as the canalicular 
multispecific organic anion transporter (cMOAT), but it now called MRP2 
(ABCC2) (Buchler et al., 1996). MRP2 is localized on chromosome 10q24 and 
consists of 32 exons encoding a polypeptide of 1545 amino acids. The membrane 
topology for MRP2 is like that of MRP1 and consists of 17 TM helices, which 
form three membrane-spanning domains (MSD0,-1 and -2) connected by 
conserved linker regions (L0 and L1) and highly conserved nucleotide-binding 
domains (NBD1 and NBD2) (Borst et al., 1999; Konig et al., 1999). 
  
MRP2 is localized on the apical membrane of polarized cells such as hepatocytes, 
enterocytes of the proximal small intestine, and proximal renal tubular cells as well 
as in the brain and placenta (Kartenbeck et al., 1996; Paulusma et al., 1999). 
Therefore, it is functionally similar to P-gp in its involvement in the terminal 
elimination of compounds and its role as a barrier in the gut and the placenta, 
which suggests that MRP2 usually performs excretory or protective roles. MRP2 is 
involved in biliary, renal, and intestinal secretion of numerous organic anions, 
including endogenous compounds such as bilirubin and exogenous compounds 
such as drugs and toxic chemicals. Its expression can be modulated in various 
physiopathological situations, notably being markedly decreased during liver 
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cholestasis and upregulated in some cancerous tissues (Paulusma et al., 1999). 
 
The substrate selectivity of MRP2 is similar to that of MRP1 but the transport 
characteristics of the pumps differ in certain details. Unlike MRP1, MRP2 is a 
lower affinity transporter for conjugates such as E217ßG, an established 
physiological substrate of the MRP1 (Morikawa et al., 2000). The drug resistance 
profile of MRP2 is similar to that of MRP1 with respect to anthracyclines, vinca 
alkaloids, epipodophyllotoxins and camptothecins. However, MRP2 appears to 
have somewhat reduced ability to confer resistance toward these agents (Koike et 
al., 1997; Cui et al., 1999; Hooijberg et al., 1999; Kawabe et al., 1999; Van Aubel 
et al., 1999; Evers et al., 2000). Another difference between MRP1 and MRP2 is 
that the latter pump is able to confer resistance to cisplatin, an agent that is known 
to form toxic glutathione conjugates in the cell (Ishikawa and Ali-Osman, 1993; 
Cole et al., 1994; Breuninger et al., 1995). Similar to the situation with MRP1, 
GSH plays a role in MRP2-mediated transport of hydrophobic anticancer agents, 
as indicated by the ability of vinblastine to stimulate GSH efflux from MRP2 
transfected MDCK cells, and the ability of rabbit MRP2 to mediate transport of 
this drug in membrane vesicle assays only in the presence of GSH (Van Aubel et 
al., 1999; Evers et al., 2000). 
 
In humans, Dubin–Johnson syndrome (DJS) is a largely asymptomatic disorder 
whose principal manifestation is jaundice. DJS is characterized by elevated 
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bilirubin, increased urinary coproporphyrin I fraction and deposition of a dark 
pigment in the liver. It was found that DJS patients lack functional MRP2 leading 
to hyperbilirubinemia and dark pigment deposition in the liver. This reflects the 
role of MRP2 in the biliary excretion of bilirubin glucuronide, a conjugate that 
results from the action of hepatic uridine 5'-diphosphate (UDP)-glucuronosyl 
transferase on the end product of heme degradation (Jedlitschky et al., 1997; 
Konig et al., 1999). 
 
1.6.3   MRP3 
The MRP3 gene is located on chromosome 17q21.3 and contains a single ORF of 
1527 amino acids, with a predicted molecular mass of 169.4 kDa. The membrane 
topology predicted for MRP3 is like that of MRP1 and MRP2 and comprises three 
MSDs connected by poorly conserved linker regions and two highly conserved 
NBDs. MRP3 is localized in liver, colon, small intestine, and adrenal gland, and is 
also expressed at lower levels in pancreas, prostate and kidney (Kool et al., 1997; 
Belinsky et al., 1998). MRP3 shares the highest degree of structural resemblance 
with MRP1 (58%) among the MRP family members. Although, its substrate 
selectivity overlaps with that of MRP1 and MRP2 with respect to the transport of 
glutathione and glucuronate conjugates, the affinity of MRP3 for conjugates is 
significantly lower than those of MRP1, and its drug resistance profile is narrower 
than that of MRP1 and MRP2. Thus MRP3 confers resistance to VP-16, MTX, but 
not to anthracyclines, platinum-containing drugs, or heavy metal oxyanions that 
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are substrates of MRP1 or MRP2 (Kool et al., 1999a; Zeng et al., 1999; Zelcer et 
al., 2001). One important class of molecules transported by human and rat 
MRP3/Mrp3 but not by MRP1 and MRP2, are monoanionic bile salts such as 
glycocholate and taurocholate, which constitute a significant component of bile 
acids in humans and rodents. This substrate selectivity, together with its induction 
at basolateral surfaces of the hepatocytes under cholestatic conditions, has led to 
the notion that MRP3 may function as a compensatory backup mechanism. When 
the usual canalicular route of excretion is blocked, MRP3 may mediate the efflux 
of organic anions from liver into blood (Leier et al., 1994; Jedlitschky et al.,1996; 
Loe et al., 1996b; Hirohashi et al., 2000; Zeng et al., 2000; Soroka et al., 2001). 
 
1.6.4  MRP4 
MRP4 was first identified by its localization to chromosome 13q32.1 by Kool et al 
in 1997 (Kool. et al., 1997). A year later, Lee et al isolated the 5.9kb MRP4 cDNA 
which encodes for a 1325 amino acids protein (Lee et al., 1998). MRP4 is 
significant smaller than MRP1, MRP2 and MRP3 because of the absence of 
MSD0 domain. Thus, MRP4 is predicted to contain 12 TM helices grouped into 
two MSDs and has a structure more typical for an ABC transporter with four 
domains (Belinsky et al., 1998; Lee et al., 1998). MRP4 mRNA is expressed most 
abundantly in prostate, and at moderate abundance in other issues, including lung, 
kidney, bladder, tonsil, liver, adrenals, ovary, testis, pancreas and small intestine 
(Kool et al., 1997; Lee et al., 1998, 2000; Schuetz et al., 2001).  
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From immunostaining of prostate tissues, MRP4 was shown to localize in the 
basolateral membrane and the basolateral cytoplasm region of basal cells (Lee et 
al., 2000). MRP4 is also present in the basolateral membrane of hepatocytes (Rius 
et al., 2003). In the kidney, MRP4 is localized on the brush border of the proximal 
tubule (Van Aubel et al., 2002). Unlike the prostate and hepatocytes, MRP4 is 
found on the apical membrane of the proximal tubule. By using quantitative PCR 
analysis, expression of MRP4 mRNA is also detected in human brain where it is 
predominantly localized in astrocytes and in the luminal (apical) side of the 
capillary endothelium of human brain (Nies et al., 2004). Thus MRP4 appears to 
be unique and can have either apical or basolateral localization depending on the 
tissue examined. 
 
MRP4 has gained a great deal of attention in recent years, because it has the ability 
to transport the anti-human immunodeficiency virus drugs 
9-(2-phosphonylmethoxyethyl) adenine (PMEA) and azidothymidine 
monophosphate (AZT) in PMEA-resistant cells (Schuetz et al., 1999; Lee et al., 
2000; Reid et al., 2003; Dallas et al., 2004). PMEA is an acyclic nucleoside 
phosphonate that acts as a stable monophosphate analogue of adenosine 
monophosphate. It exhibits activity against a variety of DNA viruses and 
retroviruses, and is used therapeutically against human immunodeficiency virus-1 
and hepatitis B virus (De Clercq E et al., 1986).  
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MRP4 and MRP5 differ in their structures from MRP1-3 in that they do not have a 
third (NH2-terminal) hydrophobic domain like MRP1-3, and this difference is 
reflected in their distinctive drug resistance profiles, substrate selectivity, and 
potential physiological functions. These two proteins do not show resistance 
against natural product anti-cancer agents as anthracyclines, vinca alkaloids or 
epipodophyllotoxins. MRP4 and MRP5 have a substrate specificity distinct from 
the other MRPs characterized to date in that they show the ability to transport 3’, 
5’-cyclic adenosine monophosphate (cAMP) and 3’, 5’-cyclic guanosine 
monophosphate (cGMP), which suggest that they might involved in the regulation 
of the intracellular concentration of these important second messengers. The cyclic 
nucleotides, cGMP and cAMP are second messengers involved in mediating the 
response to numerous stimuli, and large families of enzymes regulate their 
intracellular concentrations (Jedlitschky et al., 2000; Chen et al., 2001; Lai and 
Tan, 2002; Van Aubel et al., 2002). 
 
Although MRP4 shares a similarity of substrate selectivity of MRP5 with regard to 
transport of cAMP, cGMP, there are still differences in the drug resistance. In the 
contrast to MRP5, MRP4 has the facility for mediating the transport of 
glucuronide such as E217ßG, a compound that is an established substrate for 
MRP1, MRP2, and MRP3. However, both MRP1 and MRP2 have higher affinities 
for E217ßG than MRP4 (Chen et al., 2001, 2002; Reid et al., 2003). Another 
potential difference is that MRP4 can transport the antimetabolite MTX, while 
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MRP5 can not (Lee et al., 2000; Chen et al., 2001). The capacity of MRP4 to 
confer resistance to MTX is significant in short-term drug-exposure assays but 
modest in continuous-exposure assays, similar to that observed for MRP1, 2 and 3 
(Sierra et al., 1999; Chen et al., 2001). Similar to MRP3, MRP4 can also transport 
monoanionic bile acids (Rius et al., 2003). 
 
6-mercaptompurine (6-MP) and 6-thioguanine (6TG) have been widely used in 
acute lymphoblastic leukemia treatment. Both are purine nucleic acid analogs with 
sulfur at the C-6 position. Human embryonic kidney cells stably overexpressing 
MRP4 can transport the metabolites of these thiopurines (Schuetz et al., 1999; 
Chen et al., 2001; Adachi et al., 2002; Lai and Tan, 2002; Wielinga et al., 2002). 
6-MP and 6TG are important components of chemotherapeutic regimens used in 
the treatment of childhood leukemia, thus the ability of MRP4 to transport and 
confer resistance to both of these antimetabolites is noteworthy. In this regard 
MRP4 is unique among characterized MRP family members that confer resistance 
to either MTX (MRPs1-3) or 6-MP (MRP5) but not to both agents. Beside these 
anticancer drugs, MRP4 also mediated resistance to the antiviral agent ganciclovir 
(GCV) (Adachi et al., 2002). 
 
Similar to MRP1 and MRP2, MRP4 can also mediate the export of GSH. 
Overexpressing of MRP4 in HepG2 cells can enhance the excretion of GSH (Lai 
and Tan 2002). In addition, MRP4 can mediate the transport the fluorescent 
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glutathione conjugate, bimane-glutathione, and this transport can be inhibited by 
MTX and 1-chloro-2, 4-dinitrobenzene (Bai et al., 2004). Rius et al had found out 
that MRP4 can mediate ATP-dependent cotransport of GSH or 
S-methyl-glutathione with monoanionic bile salts, such as glycocholate, 
taurocholate and cholate. Thus, MRP4 may provide an alternative pathway for the 
efflux of GSH across the basolateral hepatocyte membrane into blood (Rius et al., 
2003). In addition to the ability to transport cyclic nucleotides, nucleoside analogs, 
glucuronide conjugates, glutathione, glutathione conjugates and bile salts, MRP4 
can also transport prostaglandins (Reid et al., 2003) and sulfate conjugates such as 
DHEAS(Zelcer et al., 2003). 
 
1.6.5  MRP5 
MRP5 was cloned by Athkmets et al in 1996 (Athkmets, et al., 1996). Human 
MRP5 (ABCC5) is located on chromosome 3q27 and encodes for a 1437 amino 
acids protein predicted to contain four domains arranged in the same manner as 
MRP4. Analysis of tissue mRNAs indicates that MRP5, like MRP1, is 
ubiquitously expressed with high transcript levels in brain, skeletal muscle, lung 
and heart and only low levels in liver (Kool et al., 1997; Belinsky et al., 1998; 
McAleer, et al., 1999). 
 
MRP5 is a GS-X pump because MRP5 has the ability of transporting GSH 
conjugate 2, 4-dinitrophenyl-GS (DNP-GS) and this transport can be inhibited by 
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typical organic anion transport inhibitors like sulfinpyrazone and benzbromarone 
but not by probenecid (McAleer et al., 1999; Jedlitschky et al., 2000; Wijnholds, 
et al., 2000). To gain insight as to whether MRP5 can confer drug resistance by 
acting as a plasma membrane drug efflux pump, Wijnholds et al did a series of 
cytotoxicity assays using nucleoside analogs. The results indicated that 
MRP5-transfected cells can confer resistance to the thiopurine anticancer drugs, 
6-MP and 6TG, and the anti-HIV drug PMEA (Wijnholds et al., 2000). Jedlitschky 
et al had examined the ATP-dependent transport of [3H] cGMP and [3H] cAMP, 
using inside-out-oriented vesicles. The data showed that MRP5 can transport 
cAMP and cGMP, but cannot transport LTC4, 17ß-glucuronosyl [3H] estradiol and 
[3H] GSSG, which are common substrates of MRP1-3 (Jedlitschky et al., 2000). In 
contrast to MRP1-3, MRP5 is unable to confer resistance against natural product 
anticancer agents as anthracyclines, vinca alkaloids, and epipodophyllotoxins 
(Wijnholds et al., 2000). 
 
1.6.6  MRP6 
MRP6 is located on chromosome 16p13.1, the same chromosome location as 
MRP1 (Kool et al., 1999b). MRP6 has 31 exons and encodes a protein of 1503 
amino acids that is glycosylated in mammalian cells to a mature protein with an 
apparent mass of 180kDa (Belinsky et al., 1999). MRP6 RNA is highly expressed 
in kidney and liver but is lowly expressed in other tissues, including skin and 
retina. Only a few tissues including the spleen, testis, bladder, heart, brain and 
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tonsil contained no detectable MRP6 (Kool et al., 1999b; Beck et al., 2003). 
 
To gain insight into the drug resistance capabilities of MRP6, CHO cells 
transfected with MRP6 expression vector were compared with similarly treated 
control transfected cells. The data showed that CHO-MRP6 cells can confer low 
level of resistance to several natural product anticancer agents as etoposide, 
teniposide, anthracyclines, doxorubicin and daunorubicn and actinomycin D.  
MRP6 can also confer resistance to cisplatin, an agent that can form glutathione 
conjugates and is also part of the MRP2 drug resistance profile (Belinsky et al., 
2002; Ilias et al., 2002). MRP6 can mediate the transport of the glutathione 
conjugates LTC4 and DNP-SG, the endothelin receptor antagonist BQ123, but not 
the glucuronate conjugate E217ßG or cyclic nucleotides. The ability of MRP6 to 
transport glutathione conjugates but not cyclic nucleotides transport is consistent 
with that of MRPs which possess a third membrane spanning domain (Belinsky et 
al., 2002).  
 
Pseudoxanthoma elasticum (PXE) is an autosomally inherited disorder that is 
associated with the accumulation of mineralized and fragmented elastic fibers in 
the skin Bruch’s membrane, in the retina, and vessel walls. Recently, it was found 
that mutations in the MRP6 gene have been responsible for PXE. Ringpfeil et al 
reported a series of pathogentic mutations in MRP6 in eight kindreds with PXE. 
Their findings indicated that the intracellular segments of MRP6 were important 
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for the normal function of the protein, and mutation involving these domains, 
result in phenotypic magnifestations of PXE. MRP6 mRNA is highly expressed in 
human kidney and liver, whereas in tissue frequently affected by PXE, including 
skin, vessel wall, and retina, the expression of MRP6 is low. It is possible that 
PXE is in fact an inheritable systemic disorder (Bergen et al., 2000; Ringpfeil et 
al., 2000; Ilias et al., 2002). 
 
1.6.7   MRP7 
MRP7, the seventh member of the MRP subfamily with cDNA sequence encoding 
1464 amino acids, is localized at chromosome 6p21.1 (Hopper et al., 2001).  
 
Hopper et al found out that MRP7 lacks a conserved N-linked glycosylation site at 
its N-terminus compared to the other MRPs that have a third (N-terminal) 
membrane spanning domain. The MRP7 transcript was detected in a variety of 
tissue by reverse transcription PCR (RT-PCR), but was not detectable by RNA blot 
analysis, suggesting that its expression is at low levels in these tissues (Hopper et 
al., 2001). 
 
MRP7 can mediate MgATP-dependent transport of E217ßG (Chen et al., 2003). 
However, there are significantly differences in the affinities of MRP pumps for 
E217ßG. MRP1 has the highest affinity, MRP7 has the lowest affinity, MRP2, 
MRP3 and MRP4 have intermediate affinities (Jedlitschky et al., 1996; Loe et al., 
 43
1996b; Cui et al.,1999; Zeng et al., 2000; Chen et al., 2001). In contrast to other 
characterized MRPs, MRP7 is the only family member that is able to confer 
resistance to taxanes. In this regard, MRP7 resembles P-gp. With respect to the 
biochemical mechanism of MRP7-mediated drug transport, the absence of 
depressed cellular levels of GSH suggests that similar to the situation with MRP3 
and in contrast to MRP1 and MRP2, MRP7 probably confers resistance to natural 
product agents in a glutathione-independent fashion (Hopper et al., 2004). 
 
1.6.8  MRP8 
MRP8 (ABCC11) was identified through EST database mining (Bera et al., 2001). 
To investigate the MRP8 tissue expression, RT-PCR was used. The data indicated 
that MRP8 is highly expressed in breast cancer, moderately expressed in normal 
breast and testis and lowly expressed in liver, brain, and placenta (Yabuuchi et al., 
2001). 
 
The MRP8 gene has two transcripts of 4.5kb and 4.1kb in length. The 4.5kb 
transcript which is abundant in breast cancer has high homology with MRP5. The 
smaller 4.1kb transcript of MRP8 is found in testis. The 4.5kb MRP8 transcript is 
encoded by the MRP8 gene located in a genomic region of over 80.4 kb on 
chromosome 16q12.1. Amino acid sequence analysis suggested that MRP8 is a 
full transporter and has two conserved nucleotide binding domains and 12 putative 
transmembrane domains (Yabuuchi et al., 2001). 
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To analyze the function characteristics of MRP8, Guo et al used LLC-PK1 cells 
transfected with MRP8 expression vector. To examine whether MRP8 is capable 
of extruding cyclic nucleotides from cells, intracellular cAMP and cGMP levels 
were analyzed before and after stimulation with forskolin and 
3-Morpholino-N-nitroso-aminoacetonitrile (SIN-1A) respectively. The data 
indicates that expression of MRP8 can result in consistent, but modest, depression 
in intracellular cAMP and cGMP levels, and enhancement of cyclic nucleotide 
extrusion. Analysis of the drug sensitivity of MRP8-transfected LLC-PK1 cells 
indicated that MRP8 has the ability to confer resistance to fluoropyrimidines 2’, 
3’-dideoxycytidine and 9-(2-phosphonylmethylethyl) adenine. In contrast to 
MRP4 and MRP5, MRP8 does not confer resistance to 6TG (Guo et al., 2003). 
Recently, it was also demonstrated that MRP8 can mediate the transport of a range 
of lipophilic anions, including the glutathione conjugate LTC4, sulfated steroids 
such as DHEAS and E1 3S, glucuronides such E217ßG, the bile constituent 
glycocholate (GC) and taurocholate (TC) and monogulatamates such as MTX 
(Chen et al., 2005). 
 
1.6.9  MRP9 
By using EST database mining and computer analysis, Bera et al identified MRP9 
(ABCC12), one year after they identified MRP8. The MRP9 gene is localized on 
16q12.1. MRP9 is a unique member of the MRP family. Most members of MRP 
family have two ATP-binding domains and at least two membrane- spanning 
 45
domains each with 6 transmembrane helices. However MRP9 only has one 
ATP-binding domain but two transmembrane domains each with four 
membrane-spanning regions. The MRP9 gene encodes two transcripts of different 
sizes. The larger 4.5kb RNA is found in breast cancer, normal breast, and testis and 
encoded an MRP-like protein that did not have transmembrane domains 3,4,11 and 
12 and the second ATP-binding domain. The smaller 1.3kb transcript is present in 
brains, skeletal muscle and ovary (Bera et al., 2002). 
 
1.7  Identification of substrate binding domains and important amino acid 
residues for MRP4 function  
 
1.7.1  Substrate binding domains  
Most of the multidrug resistance proteins of clinical importance are ABC 
transporter that confers resistance to a brand spectrum of drugs in tumor cells 
while functioning as primary active transporters of organic anions in normal cells. 
However, what determines the ability of MRPs to transport structurally unrelated 
cytotoxic drugs and conjugated organic anions remains largely unknown. Some 
structure/function studies have begun to identify domains and individual amino 
acid residues that are thought to be involved in determining substrate recognition 
and transport specificity in MRP1-related proteins.  
 
Unlike the human protein, the murine orthologue of MRP (mrp) does not confer 
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resistance to common anthracyclines and is a relatively poor transporter of E217ßG. 
Stride et al took advantage of this functional difference to identify regions of 
MRP1 involved in mediating anthracycline resistance and E217ßG transport by 
generating mrp/MRP hybrid proteins. They had demonstrated that the 
COOH-terminal third of MRP1 contains important determinants of the ability to 
confer anthracycline resistance and to transport E217ßG. Only the hybrid 
mrp/MRP959-1531 could transport E217ßG at rates comparable. They also found 
that this hybrid mrp/MRP959-1531 is capable of conferring significant resistance 
to both epirubicin and doxorubincin, while hybrid mrp/MRP1-857 was only able 
to confer low levels of resistance to epirubicin but not doxorubicin (Stride et al., 
1999).  
 
LTC4, along with other cysteinyl leukotrienes, is a mediator of immediate 
hypersensitivity reactions, acting as a potent agonist of bronchoconstriction and 
vascular permeability. Studies with mrp-/- mice have shown LTC4 to be an 
important natural substrate of MRP1 due to their impaired LTC4-mediated 
inflammatory response (Wijnholds et al., 1997). The linker region between MSD1 
and MSD2 of MRP1 was found to be essential for the transport of LTC4. This was 
identified by using a series of 5’-truncated MRP1 molecules expressed in insect 
cells (Bakos, et al., 1998; Gao et al., 1998). Furthermore, photoaffinity labeling 
studies have shown the presence of LTC4 labels sites in both the amino and 
carboxyl proximal halves of MRP1 and that labeling of the carboxyl proximal half 
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of the protein is confined to a region encompassing TM14 to TM17 of MSD2 
(Qian et al., 2001). In effort to isolate LTC4 substrate binding sites in MRP1, 
Karwatsky et al synthesized a radiolabeled photoreactive analogue of LTC4, 
arylazido- LTC4(AA LTC4) and this substrate was shown to be specific 
photoaffinity label MRP1. This was the first demonstration that a photoreactive 
analogue of LTC4 photolabels MSD0, TM12, TM10-11 and TM16-17 of MRP1 
(Karwatsky et al., 2005).  
 
1.7.2 Identification of the key amino acids  
By using site-directed mutagenesis, some specific amino acids important for 
MRP1 substrate recognition and transport activity have been identified. A series of 
studies have shown that mutation of individual aromatic, polar, and charged amino 
acids can affect the recognition and transport of one or several substrates in 
different ways. Ito et al had demonstrated that a highly conserved tryptophan at 
position 1246 is critical for the binding and transport E217ßG. Trp at position 1246 
is predicted to be at or near the membrane-cytoplasmic interface of the most 
COOH-proximal TM segment of MRP1. The data indicated that substitution of 
Trp with Cys reduced the affinity of MRP1 for LTC4, but the transport capacities 
of the mutant and wild-type proteins are comparable. On the other hand, uptake of 
E217ßG by the W1246C-MRP1 mutant was dramatically reduced and was 
comparable to that of the vector-transfected controls. In addition to the selective 
loss of E217ßG transport, W1246C-MRP1 transfected Hela cells were no longer 
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resistant to the vinca alkaloid, vincristine and accumulated levels of [3H] 
vincristine were comparable to those in vector transfected cells. Additional 
substitution of Trp with Ala, Phe, and Tyr displayed similar transport 
characteristics to those of W1246C. This was the first example of a tryptophan 
residue being so critically important for substrate specificity in a eukaryotic 
ATP-binding cassette transporter (Ito et al., 2001a). 
 
The same group later examined the effects of replacing the analogous tryptophan 
residue at position of 1254 of MRP2. Nonconservative (Ala, Cys) substitutions of 
MRP2-Trp1254 eliminated the transport of E217ßG similar to observation in MRP1. 
However E217ßG transport by the conservative substitutions (Tyr, Phe) was similar 
to that of wild-type MRP2, in marked contrast to the same substituted 
MRP1-Trp1246 mutants. Furthermore, only the most conservatively substituted 
Trp1254 mutant (MRP2-Trp1254Tyr) retained LTC4 transport activity. This contrasts 
with studies of the transport properties of MRP1-Trp1246 in which all the mutants 
showed similar affinity to this substrate as wild-type MRP1. In addition, all 
mutants MRP2-Trp1254 were unable to transport MTX (Ito et al., 2001b). 
 
Oleschuk et al had substituted the analogous residue in MRP3, Trp1242 with both 
conserved and non-conserved amino acids. The data indicated that Trp1242 in TM17 
was also important for MRP3 transport activity. Unlike substitutions of 
MRP1-Trp1246 which reduced E217ßG transport, similar replacement of 
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MRP3-Trp1242 increased transport of this substrate. The MRP3-Trp1242 
substitutions also showed the reduced transport ability of LTC4, MTX and 
leucovorin. In contrast, the MRP3-Trp1242 mutants retained their ability to transport 
taurocholic acid and E217ßG transport by these mutants could still be inhibited by 
bile acid (Oleschuk et al., 2003). 
 
Take these findings together, we can conclude that this conserved Trp residue at 
TM17 plays a pivotal role in the substrate specificity and transport capacity of 
MRP1, MRP2 and MRP3 (Table 1.4). 
 
Table 1.4  Effects of nonconservative (Ala) and conservative (Tyr) substitutions 
of MRP1-Trp1246, MRP2-Trp1254 and MRP3-Trp1242 on transport of common 
substrates. 
 
% wild-type MRP transport activity Transporter Amino acid 






























Data are from References (Ito et al., 2001a, Ito et al., 2001b,Oleschuk et al., 
2003). 
 
Koike et al had examined other membrane-associated tryptophan residues of 
MRP1 (Table 1.5). They found that Ala substitution of three residues, Trp445, 
Trp553, and Trp1198 eliminated transport of organic anion substrates (LTC4, 
E217ßG, GSH, E13SO4, MTX) by MRP1. On the other hand, Ala substitutions of 
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Trp361, and Trp459 caused a more moderate and substrate selective reduction in 
MRP1 transport function (Koike et al. 2002). These data indicated that these 
amino acids are also important determinants for substrate recognition and transport 
ability. 
 
Table 1.5  Summary of effects of nonconservative (Ala) substitutions of 
MRP1-Trp361, MRP1-Trp445, MRP1-Trp459, MRP1-Trp553, MRP1-Trp1198 on 
transport of common substrates. 
 
 
% wild-type MRP transport activity  
Mutation 
 LTC4 E217ßG GSH E13SO4 MTX 
W361A 
 
100  50 80 100 60 
W445A 
 
25 25 <10 30 20 
W459A 
 
100 100 50 25 100 
W553A 
 
50 10 <5 <10 25 
W1198A 65  Not 
detectable 
<5 20 <10 
 
Data are from References (Koike et al., 2002). 
 
Amino acid residues in MRP4 involved in the recognition and transport of its 
substrates remain largely unknown. To characterize the key amino acids that 
determine the substrate specificity, we aligned the sequence of MRP family 
(MRP1-9) and focused on Trp216, Trp230 and Phe324 (analogous Trp residues to 
MRP1- Trp445, Trp459, Trp553 respectively) (Figure 1.5). In our study, we 
substituted the above amino acids with both conserved and non-conserved amino 
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acids to examine whether these mutants affect MRP4-mediated transport and drug 
resistance.  
 
Figure 1.5  Alignment of predicted TM segments in MRP4 and the 
corresponding TM segments in other members of human MRP family. The relative 
conserved amino acids of (A) Trp216(TM3) (B) Trp230 (TM3) (C) Phe324(TM5) in 




MRP4                    209     T V F L H F L W A G P L Q A I   
MRP1                       438      A T Y I N M I W S A P L Q V I  
MRP2                       435      T N F M H M L W S S V L Q I V   
MRP3                       424      A P F L N L L W S A P L Q I I  
MRP5                       293     A A V G S L L A G G P V V A I  
MRP6                        424    V L Y L N G L W L P L V W I V  
MRP7                        398     A G S F H E A W G L P L Q L A 
MRP8                        430     F F L C P N L W A M P V Q I I  




MRP4                    228     L L W M E I G I S C L A G M  
MRP1                       457      L L W L N L G P S V L A G V   
MRP2                       454      F L W R E L G P S V L A G V  
MRP3                      443      F L W Q N L G P S V L A G V  
MRP5                       310       Y N V I I L G P T G F L G S     
MRP6                       443       Y L W Q L L G P S A L T A T    
MRP7                      414      L L U Q Q V G V A F V G G L  
MRP8                     451        L L Y Y I L G V S A L I G A  




MRP4                    311    L R S S C L R G M N L A S F F S A  
MRP1                    540    K K S A Y L S A V G T F T W V C T  
MRP2                    537    L A F S Q L Q C V V I F V F Q L T  
MRP3                    526    R T A A Y L H T T T T F T W M C S  
MRP5                    393    E K A G Y F Q S I T V G V A P I V  
MRP6                    526    I S G L L F S V S L V S F Q V S A  
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MRP7                    497    R V I K Y L D A A C V Y L W A A L  
MRP8                    534    R A F A I Y T S I S I F M N T A I  
MRP9                    337    E K A G F V Q S G N S A L A P I V  
 
1.8  Resistance to purine and nucleotide analogs 
MRP4 has the unique ability to confer resistance to cyclic nucleotides (cAMP and 
cGMP) (Jedlitschky et al., 2000; Chen et al., 2001). In addition, MRP4 
overexpressing cells also showed substantial resistance to antiviral agents such as 
the acyclic nucleoside phosphonates PMEA (Schuetz et al., 1999; Lee et al., 2000; 
Lai and Tan 2002; Reid et al., 2003) and GCV ((Adachi et al., 2002). Consistent 
with MRP4 ability to transport cyclic nucleotides, it was also demonstrated that 
MRP4 can confer resistance to purine analogs 6-MP and 6TG (Figure 1.6), which 
are important drugs in the treatment of childhood leukemia. Both are purine 
nucleobase analogs with a sulfur at the C-6 position (Chen et al., 2001; Adachi et 
al., 2002; Lai and Tan, 2002; Wielinga et al., 2002). These earlier works have 
prompted us to synthesize two series of compounds containing either the 
oxo-purine or azapurine template (Figure 1.6 and Table 1.6, 1.7) and study their 
effects on the transport properties of human MRP4.  







6TG                             azapurine  
Figure 1.6  Structures of 6TG and azapurine.  
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Table 1.6  A series of compounds which contain the purine template. These 
compounds were synthesized by Fu Han, a graduate student in Dr. Lam Yulin’s lab, 













































































































































































Table  1.7  A series of compounds which contain the azapurine template. These 
compouds were synthesized by Makam Shantha Kumar Raghavendra, a graduate 
student in Dr. Lam Yulin’s lab, Department of Chemistry, NUS. 
 
































































































































































































































































































































2.  Aims and overview of study 
Multidrug resistance proteins (MRPs) are membrane glycoproteins that mediate the 
ATP-dependent export of organic anions, including cytotoxic and antiviral drugs, 
from cells. The MRPs that have been functionally characterized so far share the 
property of ATP-dependent export pumps for conjugates with glutathione, glucuronate 
or sulfate. MRP4 was shown to be a nucleotide pump and can confer resistance to 
nucleoside analogs like PMEA and AZT, which are drugs used as anti-viral agents, 
and 6-MP and 6TG, which are used for cancer treatments. In addition, MRP4 also has 
the ability to export glutathione, glucuronide and sulfate conjugates. This project was 
carried out to examine the role of highly conserved amino acids in MRP4-mediate 
transport of the glutathione conjugate, bimane-GS and the resistance to the purine 
analog, 6-thioguanine. In addition, the effects of a series of purine analogs 
(synthesized by Fu Han and Makam Shantha Kumar Raghavendra, Department of 
Chemistry, NUS) were also examined. 
 
Figure 2.1 shows a flow chart of this study. Human HepG2 cells stably 
overexpressing MRP4 were used to perform transport study and cytotoxic assays. 
Screening of the inhibitoral effects of purine analogues on MRP4 was done by 
carrying out the bimane-GS efflux and the cytotoxic assays. In addition, we 
substituted three highly conserved amino acids located in TM helices with conserved 
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and non-conserved residues by using site-directed mutagenesis. All mutants were 
expressed in human HepG2 cells, and the bimane-GS efflux assays and the cytotoxic 
assays were carried out to see whether these amino acids play a role in MRP4 
mediated transport ability and drug resistance profiles.  
 









Full length MRP4/pcDNA-V5 plasmid 
Stable transfection into  
Human HepG2 cells 
Site-directed mutagenesis for five 
mutant clones 
Western blot to  
confirm the expression 
Immunostaining  





















to confirm the 
localization 
Bimane-GS efflux Cytotoxic assay * 
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3  Materials and Methods 
 
3.1  Generation of mutated MRP4 cDNA by using site-directed mutagenesis  
 
3.1.1  Materials 
Primers for PCR (polymerase chain reaction) were purchased from PROLIGO 
Singapore Pte. Ltd. Luria Broth (LB) medium and 10x TAE buffer were purchased 
from National University Medical Institute (NUMI). LB medium contains 10 g of 
tryptone, 5g of NaCl and 5 g of yeast extract in 1L deioned water, the pH was set 
to 7.4. LB medium was kept at 4ºC. Ampicilllin was bought from Sigma. The 
restriction enzymes were purchased from New England Biolabs, USA. pGEM-T 
vector were obtained from Promega, while pcDNA6 vector and blasticidin 
selection marker were purchased from Invitrogen, USA. 
 
3.1.2  Primers design and PCR 
The PCR technique was used to exponentially amplify target DNA sequences 
using the specific sequence primers. The thermostable enzyme Taq DNA 
polymerase was used in this cycling reaction on a thermal cycle. One pair of 
primers was used to amplify the DNA that contains the mutation site together with 
downstream sequence. The reverse primer (rm) contains the mutation to be 
introduced into the template DNA, whereas the forward primer (F) complements 
completely to the template with a restriction site in the 5’ region to facilitate 
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subcloning of the mutated segment of DNA. The second pair of primers was used 
to amplify the DNA that contains the mutation site together with upstream 
sequence. The forward primer (fm) contains the mutation whereas the reverse 
one(R) complements the template with another restriction site in the 3’ region. 
Primers used for mutagenesis were listed in Table 3.1. 
 
Using two sets of primers and the wild type MRP4 as the template to amplify 
overlapping fragments, the first round PCR contained two separate reactions. The 
mutation site was located in the overlap region and was therefore present in both 
sets of amplified fragments. The second round PCR was processed using the two 
end primers (F and R) and a mixture of the first round PCR products as template to 
generate a full-length mutant fragment.    
 
PCR was performed using the QIAGEN PCR system. A typical 50 μl reaction 
contained 5 μl 10 x PCR buffer, 1μl 10mM dNTPs mixture, 1μl template DNA, 
1μl of both primer and 1μl Taq polymerase and 40μl ddH2O. The mixture was 
subjected to the following thermal cycling for 35 cycles. The PCR products were 





Table 3.1   Primers for mutagenesis. Substituted nucleotides are underlined; small 
letters indicate restriction enzyme recognition sequence. 
 
Name of mutant Primers 
W216A  
(original amino acid 
W was mutated to A) 
F:  5’-TCC gaa ttc ATG CTG CCC GTG TAC CA- 3’ 
RM: 5’-C TGC TGC CAG GAA GTG-3’ 
FM: 5’-CAC TTC CTG GCA GCA G -3’ 
R:  5’-TGC GAA TTC ATG CTG CCC gtg tac CA-3’ 
W230F 
(original amino acid 
W was mutated to F) 
F:  5’-TCC gaa ttc ATG CTG CCC GTG TAC CA- 3’  
RM: 5’-TAT CTC CAT GAA GAG TAG GGC-3’ 
FM: 5’-GCC CTA CTC TTC ATG GAG ATA-3’ 
R:  5’-TGC GAA TTC ATG CTG CCC gtg tac CA-3’ 
W230A 
(original amino acid 
W was mutated to A) 
F:  5’-TCC gaa ttc ATG CTG CCC GTG TAC CA- 3’ 
RM:5’-TAT CTC CAT TGC GAG TAG GGC-3’ 
FM:5’-GCC CTA CTC GCA ATG GAG ATA-3’ 
R:  5’- TGC GAA TTC ATG CTG CCC gtg tac CA-3’ 
Denaturation        94ºc       1 min
Annealing          55ºc       1 min  
Extension         68ºc     1 min/kb DNA 
 34 cycles 
Final extention      68 ºc      3 min 
Initial denaturation   94ºc        2 min 
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F324W 
(original amino acid F 
was mutated to W) 
F:  5’-TCC gaa ttc ATG CTG CCC GTG TAC CA- 3’ 
RM:5’-TGC ACT GAA CCA CGA AGC CAA-3’ 
FM:5’-TTG GCT TCG TGG TTC AGT GCA-3’ 
R:  5’- TGC GAA TTC ATG CTG CCC gtg tac CA-3’ 
F324A 
(original amino acid F 
was mutated to A) 
F:  5’-TCC gaa ttc ATG CTG CCC GTG TAC CA- 3’ 
RM:5’-TGC ACT GAA AGC CGA AGC CAA-3’ 
FM:5’-TTG GCT TCG GCT TTC AGT GCA-3’ 
R:  5’- TGC GAA TTC ATG CTG CCC gtg tac CA-3’ 
 
3.1.3  Agarose Gel Electrophoresis 
Analysis of DNA fragments was carried out by electrophoresis on horizontal 
agarose gels. To prepare 1% agarose gels, 0.4g of agarose (BioRad) was dissolved 
in 40ml of 1x TAE buffer (40mM Tris, 2mM EDTA, and 1.14% glacial acetic acid 
at pH 7.8 , purchased from NUMI) with 500μg/L ethidium bromide (BioRad) by 
boiling in a microwave oven for 1 min, and cooled to about 50ºC. The mixture was 
poured into a mini gel casting chamber, and the comb was inserted. When the gel 
had solidified, the comb was removed and the chamber with the gel was placed 
into an electrophoresis tank. The DNA samples were mixed with 1/5 volume of 
loading buffer (BioRad) before loading into the well. The DNA ladder (BioRad) of 
the appropriate size (100bp or 1kb) was also loaded. Electrophoresis was 
performed at 80-100 volts for 30-50 mins or until the bromophenol blue dye-front 
moved to 2/3 of the length of the gel. The gel was taken out from the tank, viewed 
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with UV transilluminator and a photograph was taken. 
 
3.1.4  Gel extraction of DNA 
After agarose gel electrophoresis, DNA fragments of interest were isolated for 
further use. The QIAquick Gel Extraction Kit (QIAGEN) was used to perform 
DNA gel extraction. After electrophoresis, the DNA fragment of interest was 
excised from the gel with a scalpel. The gel slice was then weighed in a 2-ml tube. 
3 volumes of Buffer QG was added to the gel slice (100 mg of gel =100 μl) and 
incubated at 50ºC for 10 mins. 1 volume of isopropanol was then mixed with the 
sample, which was then applied to the QIAquick column, and was spun for 1 min 
at 12,000 x g. The flow-through was discarded. The column was washed with 
0.75ml of buffer PE and the tube was centrifuged twice for 1 min at 12,000 x g to 
completely let buffer PE flow through. The washed QIAquick column was then 
placed into a clean 1.5 ml tube. To elude the DNA, 30μl of Buffer EB or sterile 
water was added directly onto the membrane in the column, and the column was 
incubated for 1 min at room temperature before centrifugation at 12,000 x g for 
1min to collect the DNA.  
 
3.2  TA sub-cloning 
 
3.2.1  Ligation of PCR products to a TA cloning vector 
The subcloning of the DNA fragments amplified by PCR was carried out by using 
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the pGEM-T vector (Promega). The pGEM-T vector system is a convenient 
system for the cloning of PCR products. The vector with unpaired 3’ thymidyl 
residue can be readily ligated with the PCR products that have the additional 
adenine residue at the 5’ ends. Taq polymerase will add an adenine at the 5’ end of 
the PCR product. The vector has an ampicillin resistance gene and a 
ß-galactosidase gene, so the ampicillin and white-blue screenings can be used. 
 
A 10 μl ligation reaction system consisted of 1 μl pGEM-T vector (60 ng), 1 μl T4 
DNA ligase (5 units), 5 μl 2 x rapid ligase buffer (both are in the pGEM-T vector 
system kit) and 3 μl PCR purified product by gel extraction. The molar ratio of 
insert DNA to vector was kept at 3:1 to ensure the maximum insertion of both 
cohesive and blunt-ended ligation. The concentration of PCR product can be 
estimated by comparison to DNA mass standards on a gel. To calculate the 
appropriate amount of PCR product (insert) to include in the ligation reaction, the 
following equation was used. 
 
The mixture was incubated for 1 hour at room temperature or overnight at 4 ºC to 
get the maximum number of colonies after transformation. 
 
ng of vector × kb size of insert X insert vector molar ratio = ng of insert 




Figure 3.1  Map of pGEM-T vector (promega). The vector is prepared by cutting 
Promega’s pGEM-5Zf (+) vectors with EcoRV and adding a 3’terminal thymidine 
to both ends.  
 
3.2.2  Culture Media and plates 
LB medium was purchased from NUMI. LB medium contains 10 g of tryptones, 5 
g of NaCl, 5 g of yeast extract in 1L deionized water, pH 7.4. LB medium was kept 
at 4ºC till required.  
 
Ampicillin was purchased from Sigma. Ampicillin was dissolved in ddH2O at the 
concentration of 100mg/ml as a stock. The solution was filtered through a 0.22 μm 
filter (Minisart). The stock was kept at -20ºC. The LBA (LB with ampicillin) 
medium which contained 100μg /ml ampicillin was kept at 4ºC. 
 
To prepare LBA-agar plates, 20g agar grade from Becton Dickenson was added to 
1 L LB medium before being autoclaved at 121ºC for 20 mins. The autoclaved 
LB-agar medium was allowed to cool to 50ºC and ampicillin was added at the 
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final concentration of 100μg /ml. 30-35ml of medium was poured into 85mm Petri 
dishes and left to solidify at room temperature. The LBA-plates were kept at 4º for 
up to 1 month. 
 
3.2.3  Culturing and storing bacterial cells 
 
3.2.3.1  Bacterial strains  
Strains of Escherichia coli (E .coli) were kept in LB medium containing 10% 
glycerol at -80 ºC for long-term storage. For E. coli strains containing plasmids, 
the media were supplemented with the appropriate antibiotics at a final 
concentration of 100μg/ml. The bacteria were cultured in LB/LBA broth or 
streaked onto LB/LBA plates.  
 
3.2.3.2  Prepare competent cells 
The bacteria used for transformation is the DH5α strain. Competent cells used for 
heat shock transformation were prepared by using calcium chloride. An overnight 
culture was prepared by inoculating a colony from the LB-agar plate into 2 ml of 
LB media and incubated at 37ºC with shaking at 200 x g. 1 ml of the freshly 
grown overnight culture was transferred to a tube containing 20 ml of LB the next 
day and incubated at 37ºC with shaking at 200 x g until the cells had grown to an 
absorbance value of 0.3-0.4 at 600nm. The cells were harvested by centrifugation 
at 3000 x g for 5 mins at 4ºC, the supernatant was discarded and the bacteria pellet 
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was resuspended totally in 5 ml ice-cold 0.1 M CaCl2. After 15 mins of incubation 
on ice, the cells were spun at 3000 x g at 4ºC for 5 mins again, the supernatant was 
discarded. 1 ml of 0.1 M cold CaCl2 was used to resuspend the cells. After 15 mins 
of incubation on ice, the competent cells were ready for transformation. 
 
3.2.3.3  Transformation (heat shock protocol)  
5μl of the ligated product was diluted with 25 μl sterile TE buffer, and 200 μl of 
freshly prepared competent cells was added. The mixture was left on ice for 30 
mins. The mixture was then heat-shocked at 42ºC for 90 seconds and promptly 
transferred back to ice for 2 mins. 500 μl of LB was added and the tubes were 
incubated at 37ºC for 45 mins with vigorous shaking at 200 x g to allow the 
recovery of the cells and the expression of the plasmid-encoded 
ampicillin-resistance gene. 50μl of 25 mg/ml  5-bromo-4-chloro-3-indolyl-β-D- 
galactopyranoside (X-gal) (BioRad) and 50μl of 0.1mM isopropyl-β 
-D-thiogalactopyranoside (IPTG) (Sigma) were spread over the surface of an LBA 
plate and allowed to absorb for 30 mins at 37ºC prior to use. 200 μl of transformed 
cells was spread on the LBA plate containing X-gal and IPTG. The plate was then 
incubated overnight at 37 ºC. 
 
3.2.3.4  Selection and Screening 
The next day, a single white colony was picked up and inoculated in the 3ml LBA 
medium in a loosely capped green cap tube. The culture was incubated overnight 
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at 37ºC with shaking at 200 x g. 
 
3.2.3.5  Small-scale DNA extraction (mini prep) 
 
3.2.3.5.1  Solutions  
Solution I consisted of 25 mM Tris (pH8.0), 10 mM EDTA (pH8.0) and 50 mM 
glucose. Solution II consisted of 0.2 M NaOH and 0.1% SDS. Solution III 
consisted of 3.0 M potassium acetate and 0.5 M acetic acid at pH 4.8 and was 
freshly prepared just before use. 
 
3.2.3.5.2 Small-scale DNA extraction (alkali lysis method) 
The alkali lysis method was used for the rapid isolation of plasmid DNA on a 
small-scale. Typically, 1.5 ml of overnight bacteria culture was centrifuged at 
14,000 x g for 1 min, the supernatant was discarded and the pellet was 
resuspended in 100μl of ice-cold solution I by vigorous vortexing. Lysis of the 
bacteria occurred when the bacterial suspension was mixed with 200μl of freshly 
prepared solution II by gently inversion 5 times. After 2 mins of standing on ice, 
150μl of ice-cold solution III was added to neutralize the mixture and renature the 
plasmid DNA. The tube was then vortexed for 10 seconds and placed on ice for 5 
mins. The cell debris and the chromosomal DNA were removed by centrifugation 
at 14,000 x g for 5 mins. The supernatant was transferred to a new tube, 900μl of 
100% ethanol was added to precipitate the DNA and the tube was vortexed to mix 
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completely. After 5 mins at room temperature, the tube was centrifuged for 5 mins 
and the pellet was rinsed with 1 ml of 70% ethanol. The tube was then centrifuged 
for 5 mins again. The supernatant was discarded, the pellet was dried in the 
speed-Vacuum machine. Care was taken to avoid over-drying the pellet. Before 
further analysis, the pellet was dissolved in 25μl of TE buffer with 20μg/ml RNase 
(Promega). To degrade RNA contaminants, the dissolved plasmid was incubated at 
37ºC for 30 mins. The sample was stored at -20ºC. 
 
3.2.3.6  Restriction enzyme digestion 
Restriction enzyme digestion of DNA was usually carried out in a total volume of 
10μl. The digestion reaction mixture usually consisted of 0.5μl (4-10 units) of each 
enzyme, 1μl buffer 3, 1μl BSA, 5μl DNA in TE buffer and 2μl sterile water. The 
tube was incubated at 37ºC for 1-2 hours. After incubation, agarose gel 
electrophoresis was used to check the digestion.  
 
3.2.3.7  Large-scale DNA extraction (midi prep) 
QIAGEN midi plasmid preparation kit was used to perform a large scale plasmid 
preparation and purification (midi-prep). 1 ml bacteria culture carrying the correct 
plasmid was grown in 100 ml LBA medium at 37ºC with vigorous shaking 
overnight. The next day, the bacteria cells were harvested by centrifugation at 
5,000 x g for 15 mins at 4ºC. After centrifugation, the supernatant was discarded 
and the pellet was resuspended completely in 4 ml of ice-cold Buffer P1 by 
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vortexing. 4 ml of Buffer P2 was added and the tube was then inverted several 
times to mix totally. Following 5 mins of incubation at room temperature, 4 ml of 
ice-cold Buffer P3 was added and the tube was inverted several times. After 15 
mins of incubation on ice, the tube was then centrifuged at 13,000 x g for 30 mins 
at 4ºC. The supernatant was transferred to a QIAGEN-tip 100 column that had 
been equilibrated with 4 ml of Buffer QBT in advance and was allowed to flow 
through the column. The column was then washed twice with 10 ml buffer QC 
each time and the DNA was eluted with 5 ml Buffer QF. The eluate was collected 
in a new tube and mixed with 3.5ml isopropanol (Sigma). After 15 mins of 
incubation at room temperature, the tube was centrifuged again. The pellet was 
rinsed with 1.5 ml of 70% ethanol and centrifuged again. The pellet was dried in 
the speed –vacuum machine and dissolved in 100μl TE buffer.  
 
The concentration and the purity of product were determined by measuring 
absorbance at 260 nm and 280 nm. The DNA was subjected to appropriate 
restriction enzyme digestion followed by agarose gel electrophoresis analysis and 
the identity was confirmed by DNA sequence. The DNA was stored at -20ºC. 
 
3.2.3.8 DNA sequencing 
The introduction of chain-terminating dideoxynucleoside triphosphates (ddNTPs) 
is the basis for enzymatic methods of DNA sequencing. By using the four different 
ddNTPs in four separate enzymatic reactions, populations of oligonucleotides are 
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generated that terminate at positions occupied by every A, C, G or T in the 
template strand. DNA sequencing was carried out on denatured, double stranded, 
covalently closed circular DNA constructs using vector-specific forward and 
reverse primers and a series of insert-specific primers (based on the insert 
sequence). In this study, BigDye TerminatorTM Cycle Sequencing Ready Reaction 
Kit (ABI PRISM Corp) was used for sequencing. The sequencing reaction mixture 
consisted of 8μl of Terminator Ready Reaction mixture, 1μl of DNA template, 1μl 
of 50μM appropriate primer (forward & reverse primer respectively) and 10μl of 




For each sequencing reaction, a 0.6 ml microcentrifuge tube containing 3μl of 3 M 
sodium acetate, 62.5μl of 95% ethanol, 14.5μl deionized water and 20μl PCR 
product were prepared. The tube was vortexed to mix completely. After being left 
at room temperature for about 30 mins, the tube was centrifuged at 14,000 x g for 
20 mins. The supernatant was carefully removed and the pellet was rinsed with 
250μl of 70% ethanol and centrifuged for 5 mins at 14,000 x g. The supernatant 
was removed, the pellet was air-dried and then sent to the NUMI sequencing lab 
Denaturation            96ºc      30 sec 
Annealing              50ºc      15 sec 
Extension              60ºc       4 min 
 24 cycles 
Initial denaturation       96ºc       1 min  
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for sequencing. The result was compared to the published MRP4 sequence 
(GenBank access number AF071202). 
 
3.2.3.9  Construction of expression plasmid 
pcDNA6/V5-His (pcDNA6) is a eukaryotic expression vector with the V5 epitope 
and a polyhistidine sequence at the end of multiple cloning sites. This was  used 




Figure 3.2  Map of pcDNA6/V5-His vector (Invitrogen). The EcoRI and XhoI 
sites were used for cloning.  
 
Full-length MRP4-cDNA without the stop codon, but with EcoRI and XhoI 
restriction sites engineered at the 5’-and 3’-ends had been subcoloned into pcDNA 
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vector to generate the MRP4-pcDNA6 construct (Lai and Tan, 2002). From the 
clones in pGEM-T vector, the mutated fragments with the restriction enzyme sites 
of EcoRI and EcoRV at each end were digested and used to replace the wild-type 
fragment in the MRP4- pcDNA6 construct. 
 
3.3  Cell line and cell culture 
 
3.3.1  Materials 
Dulbecco’s Modified Eagle Medium (DMEM) (Sigma) was purchased from 
NUMI. Fetal bovine serum (FBS) was purchased from Sigma. Sodium pyruvate 
and non essential amino acids were purchased from Life Technologies, USA. 
Glutamine and penicillin/streptomycin were purchased from Sigma Chemical Co, 
USA. Blasticidin was purchased from Invitrogen, USA. OPTI-MEM I Reduced 
Serum Medium and Lipofectamine reagent were purchased from Invitrogen, USA. 
Dimethyl sulfoxide (DMSO) was purchased form Sigma.  
 
3.3.2  Cell line  
HepG2 cells which stably expressed human MRP4 protein (MRP4/HepG2) and the 
Vector/HepG2 cell which was stably transfected with pcDNA6 vector were used. 
Cells were routinely grown in complete medium consisting of DMEM Medium, 
1mM sodium pyrubate, 2mM glutamine, 0.1mM non-essential amino acids, 100 
unit/ml penicillin, 100μg/ml streptomycin, 10% fetal bovine serum and 0.25μg/ml 
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blasticidin. The cells were grown at 37ºC in a humidified atmosphere of 95% air 
and 5% CO2. To ensure continual overexpression of MRP4 in HepG2 cells, 
blasticidin was added at final concentration of 0.25μg / ml in the medium.  
 
3.3.3  Cell culture 
 
3.3.3.1  Initiating a new flask  
1 ml of frozen cells was taken from the liquid nitrogen tank and thawed at 37ºC. 
This was then transferred to a 15-ml tube and diluted with 10 ml medium. The 
tube was then centrifuged at 1000 x g for 5 mins. After the supernatant was 
discarded, the pellet was resuspended in 7 ml medium in a 25 cm2 flask and kept in 
a humidified atmosphere of 95% air and 5% CO2 at 37 ºC. 
 
3.3.3.2  Passaging Cells 
When the flask was 95% confluent, the cells were passaged. The cells were rinsed 
with PBS (phosphate-buffered saline, 137mM NaCl, 2.7nM KCl, 4.3mM Na2HPO4, 
1.47mM KH2PO4, pH 7.4) twice after the old medium was removed. 1 ml of 
trypsin was added and spread over the 25cm2 flask. After about 5 min of 
incubation at 37°C, the cells were detached. The appropriate volume of cell 
suspension was then transferred to a new 25 cm2 flask with 7 ml of fresh medium. 
 
3.3.3.3  Harvesting Cells 
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The cells were washed twice with PBS and trypsinized after the used medium was 
removed. The detached cells were transferred to a 15-ml tube, resuspended in 
10ml DMEM, and centrifuged at 1000 x g for 5 mins. The pellet was then 
resuspended in 1 ml PBS and centrifuged at 1000 x g for 5 mins. The pellet was 
stored at -80ºC. 
 
3.3.3.4  Freezing cells 
The cells were washed twice with PBS and trypsinized after the used medium was 
removed. After the detached cells were resuspended in 10 ml medium and 
centrifuged at 1000 x g for 5 mins, the pellet was resuspended in 1 ml FBS 
containing 10 % DMSO and then transferred to nunc cryotubes, which were firstly 
kept at -80ºC for one week and then transferred to the liquid nitrogen tank for 
long-term storage. 
 
3.3.4  Transfection and selection of mutated MRP4 
To generated stable cell lines with mutant MRP4, lipofectamine was used to 
transfect mutant MRP4 cDNA constructs into HepG2 cells. OPTI-MEM I Reduced 
Serum Medium and Lipofectamine reagent were purchased from Invitrogen, USA. 
Mutant MRP4 in pcDNA6 vector was transfected into HepG2 cells. Wild-type 
MRP4 and empty pcDNA6 vector were included as controls. HepG2 cells were 
seeded into six-well plates (35-mm) at the density of 4 x 105 cells per well one day 
before transfection. 4μg of precipitated plasmid DNA was dissolved into 100μl of 
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OPTI-MEM I Reduced Serum Medium while 6μl of Lipofectamine reagent was 
diluted with another 100μl of OPTI-MEM I Reduced Serum Medium. The two 
solutions were mixed gently and incubated at room temperature for 45 min to 
allow the DNA-liposome complex to form. During the incubation, the cells in 
six-well plates were washed twice with 1 ml of OPTI-MEM I Reduced Serum 
Medium. After the 45 mins incubation, the 200μl mixture was gently added into 
each well which also contained 0.8 ml of OPTI- MEM I Reduced Serum Medium. 
After 5 hours of incubation in a 37ºC humidified incubator, 2 ml of complete 
DMEM medium was added into each well and the cells were incubated overnight. 
The next day, the old medium was removed, the cells were washed with PBS and 
fresh DMEM medium was added. After 24 hours, DMEM medium with  
1μg/ml blasticidin for selection was added. This was changed every 2 days for 
about 3-4 weeks until single colonies were obvious. The single colonies were 
picked and plated into a 96-well plate. Those colonies were expanded until they 
were sufficient to grow in 75cm2 flasks.  
 
3.3.5  Immunostaining 
5 x 103 cells were seeded on a chamber slide. The cells were incubated overnight 
at 37ºC in DMEM medium or until they reach 50% confluence. After 24 hours, the 
medium was removed and the cells were washed twice with 500μl of PBS. The 
cells were then fixed with methanol at room temperature for about 5 min, and 
washed five times with 500μl PBS. After washing, the cells were permeablized 
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with 500μl blocking buffer (PBS containing 10% FBS) for 20 min at room 
temperature. After removing the blocking solution, the cells were then stained with 
the anti-V5-FITC Ab (from Invitrogen) diluted in the ratio of 1: 500 with PBS 
containing 10% FBS for 1 hour at room temperature in the dark. After the cells 
were thoroughly washed 5 times with PBS, cells were incubated in 1μg/ml 
propidium iodide (Sigma) solution for 5 min. The cells were then examined with a 
fluorescence microscope equipped with a 495 nm excitation filter and a 525nm 
emission filter.   
 
3.3.6  SDS-Polyacrylamide gel electrophoresis  
 
3.3.6.1  Preparation of reagents and solutions 
To prepare 4 x separating buffer (1.5M Tris-HCL), 18.17g Tris base and 4 ml 10% 
SDS were dissolved in 100 ml H2O and the pH was adjusted to 8.8 by using HCL. 
100 ml of 4 x stocking buffer (0.5M Tris-HCL) contained 6.06g Tris base and 4 ml 
10% SDS and the pH was adjusted to 6.8 by using HCL. 1 L of 10 x 
polyacrylamide running buffer contained 30 g Tris base, 144 g lysine and 100ml 
10% SDS. 10 ml of 4 x sample buffer contained 0.0185g bromophenol blue, 0.8 g 
SDS, 10 ml of 4 x stacking buffer and 8 ml glycerol. TEMED (N N, 
N’N’-Tetra-methyletylenediamine) was obtained from BioRad. Ammonium 
persulfate (AP) was obtained from Sigma. 100 mg/ml AP solution was prepared 
freshly before use. 1 L of 10 x transfer buffer contained 30.3 g Tris-base, 144.0 g 
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glycine. 1L of 10 x TBS-T contained 60.5 g Tris-base, 87.6 g NaCl, 10 ml 
Tween-20 and the pH was adjusted to 7.5. Acrylamide solution (30%) consisted of 
30 g acrylamide and 0.8 g bisacrylamide in 100ml H2O.  
 
3.3.6.2  Determination of protein concentration 
All protein concentrations were determined by the Bradford micro-assay procedure 
using the Bio-Rad Protein Dye. Absorbance was measured at 595 nm. A standard 
curve was drawn using bovine serum albumin (BSA) at concentrations ranging 
from 0.1-0.9 mg/ml.  
 
3.3.6.3  Preparation of Sample 
When the cells were about 70%-80% confluent in a 75cm2 flask, 1 ml of PBS with 
2% Triton X-100 was added into the flask. Care was taken to ensure that the 
bottom of the flask was completely covered with PBS/Triton X-100. The flask was 
allowed to stay on ice till all the cells were washed down. The cell mixture was 
taken out from the flask and centrifuged at 14,000 rpm at 4ºC for 20 min to 
remove the cellular debris, and the supernatant was kept for analysis. To ensure 
that the same amount of protein from different samples was applied, protein 
concentrations were determined by using the Bio-Rad Protein Dye with bovine 
serum albumin as the standard. About 30 µl of supernatant (corresponding to 
0.5mg protein) was then mixed with 10 µl of SDS 4x sample buffer and 1.5 µl 
β-mercaptoethanol. 
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3.3.6.4  Gel formulation 
10 ml of 8% resolving gel contained 4.7 ml deionized water, 2.7 ml of 30% 
degassed Acrylamide/Bis, 2.5 ml of 1.5M Tris-HCL (pH8.8) and 0.1 ml of 10% 
SDS. 50μl of 10% APS and 5μl TEMED was added immediately prior to pouring 
the gel.  
 
10 ml of 4% stacking gel contained 6.1 ml deionized water, 1.3 ml of 30% 
degassed Acrylamide/Bis, 2.5 ml of 0.5M Tris-HCL (pH6.8) and 0.1 ml of 10% 
SDS. 50μl of 10% APS and 10μl of TEMED was added before pouring the gel.  
 
3.3.6.5  Procedure 
The resolving gel solution was mixed and allowed to degas before adding AP and 
TEMED. The reagents were quickly mixed and poured into a mini-gel casting 
chamber. A depth of 2.5cm from the top was left empty. Water was overlaid to 
cover the separating gel. When the separating gel had solidified, the water was 
removed; the stacking gel was prepared and poured on top of the separating gel. A 
comb was inserted into the stacking gel. After the stacking gel solidified, the comb 
was removed. 20 µl of sample or 10 µl of prestain protein ladder (BioRad) was 
loaded into each well. The gel was then electrophoresised at 140 volts for 60 min 
or till the dye front ran near the bottom of the gel.  
 
The separating gel was soaked in the transfer buffer together with the 
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nitrocellulose membrane and filter paper of the same size as the gel for about 40 
min. The gel sandwich was stacked in the following order: filter paper, gel, 
nitrocellulose membrane followed by another piece of filter paper. The sandwich 
was placed into an electro-transfer apparatus filled with transfer buffer (25mM Tris, 
0.2M glycine, 0.05% SDS, 20% methanol. pH 8.3). The proteins were transferred 
from gel onto the nitrocellulose membrane at 350 mA for 60 min at 4ºC. The 
membrane was then blocked overnight in 30 ml of blocking buffer (1x TBS-T with 
5% non-fat milk). The next day, after washing with TBS-T buffer twice, the 
membrane was cut into two pieces to separate the MRP4 protein and actin. The 
membrane was then incubated in 5 ml of blocking buffer containing 1:1000 diluted 
anti-V5 monoclonal antibody (Sigma, USA) or 1:500 diluted anti-actin antibody 
(Sigma, USA) for 2 hours. The membrane was then washed with TBS-T buffer 
three times and then incubated in blocking buffer containing 1:2000 diluted goat 
anti-mouse antibody (BioRad) for MRP4 or 1:5000 diluted anti-rabbit antibody for 
actin (ECL kit, Amersham) for 1 hour. The membrane was then thoroughly washed 
with TBS-T buffer to remove the excess secondary antibody. The membrane was 
then submerged in a mixture of equal volume of luminol solution and stable 
peroxide solution (ECL kit, Amersham) and incubated for 5 min. The membrane 
was removed from the mixture, wrapped in cling film and placed against the film 
(Pierce) in the cassette. The film was developed after sufficient exposure.  
 
3.3.7  Expression of quantitation 
 84
Relatively levels of protein expression were analyzed by densitometric analysis 
using the Analytical Imaging Station software (Imaging Research Inc, USA). 
 
3.4  Functional study of MRP4  
 
3.4.1  Materials 
6-thioguanine (6TG) and equine liver glutathione-S-transferase (GST) were 
purchased from Sigma Chemical Co, USA. Glutathione (GSH) was obtained from 
ICN Biomedicals Inc, while monochlorobimane (MCB) was purchased from 
molecular Probes Inc, USA. 
［ 3,(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-t
etrazolium］ /phenazine ethosulfate (MTS/PES) reagent was supplied as the 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay by Promega, USA.  
 
3.4.2  Cytotoxicity Assay 
Cells were plated in triplicate at the density of 4 x 103 per well in 96-well tissue 
culture plate in a volume of 200μl of complete medium. After 24 hours of 
incubation at 37ºC, the medium was changed and 6TG was added at various 
concentrations. Control cells were incubated either with medium containing 0.1% 
DMSO or in medium only. 48 hours later, 20μl of MTS (Promega) was added to 
each well. After incubation at 37ºC for 60 mins, absorbance was measured at 490 
nm. The data was used to calculate the 50% growth inhibitory concentration (IC50). 
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At least five drug concentrations were used to determine the IC50 value.  
 
3.4.3  Export assay using MCB 
Monochlorobimane (MCB) is a cell-permeant and essentially nonfluorescent probe, 
which is conjugated to GSH by glutathione S-transferase to form a 
cell-impermeant and fluorescent bimane-glutathione conjugate. This property of 
the bimane-glutathione conjugate has been used to assay the MRP4-mediated 
export of glutathione conjugate (Bai et al., 2004). For this assay, cells were seeded 
in triplicate at a density of 6 x 105 cells per well into 6-well multi-well plates and 
incubated at 37ºC for 24 hours. The next day, the medium was removed and the 
cells were incubated with 1 ml DMEM medium containing 100uM MCB at 10oC 
for 60 mins. After pretreatment with MCB, the plates were placed on ice, the 
medium was removed and the cells were washed with cold HBSS (Hanks’ 
balanced salt solution, containing 5.8 mM K+, 143 mM Na+, 1.3 mM Ca++, 0.8 
mM Mg ++, 146 mM Cl -, 0.8 mM phosphate, 4.2 mM HCO3- and 10mM Hepes, 
pH 7.4) without glucose twice (1-2 ml). The cells were incubated with 0.6 ml 
HBSS/with glucose (5.6 mM) at 37oC. At the designated times, the plate was 
placed on ice and 200ul aliquots of incubation buffer were collected and placed 
into a 96-well plate. The cells were solubilized with 0.6 ml of 0.2% Sodium 
Dodecyl Sulfate (SDS) and the cells were detached with a rubber policeman. 200ul 
aliquots of cell lysate were collected and placed into a 96-well plate. The 
bimane-GS content in the sample was measured by determining the fluorescence 
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intensity at an excitation wavelength of 385 nm and an emission wavelength of 
478 nm in a Gemini XS microplate spectrofluorometer from Molecular Devices 
Corp, USA. The protein determination was carried out by using Bio-Rad Protein 
Dye with bovine serum albumin dissolved in 0.2% SDS as the standard. 
 
To quantify the amount of bimane-GS, a series of bimane-GS standards were 
generated. 0-48 μM of MCB, 1 U/ml equine liver GST in HBSS buffer (or in 
HBSS buffer containing 0.2% SDS for cell lysate) were mixed and incubated until 
no increase in fluorescence was observed. After 30 mins of incubation in a 37ºC 
water bath, the fluorescence of the standards was read using an excitation 
wavelength of 385 nm and an emission wavelength of 478 nm in a Gemini XS 
microplate spectrofluorometer (Molecular Devices Corp, USA). A calibration 
curve was obtained and the fluorescence of the sample was then correlated with 
the curve. 
 
3.4.4  Effects of synthesized compounds on bimane-GS efflux and drug 
resistance 
A series of novel oxo-purine and azapurine compounds were synthesized (by Fu 
Han and Makam Shantha Kumar Raghavendra, Department of Chemistry, NUS) 
and made available for this study. To gain insight into the effect of these 
compounds on the transport of bimane-GS, the cells were incubated in 1 ml 
DMEM containing 100 µM MCB at 10°C for 1 hour with different concentrations 
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of synthesized compounds. Controls consist of cells incubated with DMSO, which 
was used to dissolve the compounds. The efflux was carried out as described 
section in 3.4.3.  
 
To examine the role of these synthesized compounds on the MRP4-mediated 
resistance of 6TG, the cells were treated with 6TG as well as the compounds of 

















4.  Results 
 
4.1  Cloning and expression of mutant MRP4 
 
4.1.1 PCR 
By using the full-length MRP4 cDNA in pcDNA6 vector as the template, MRP4 
cDNA fragments containing mutant sites were generated. Primers used for the 
PCR were based on the published MRP4 sequence (GenBank access number 
AF071202). For each mutant, two fragments consisting of the same overlapped 
mutant nucleotide were generated in the first round of PCR. These served as the 
template for generating the mutant MRP4 fragments during the second round of 
PCR. For this study, five mutants corresponding to changes at amino acid residues 
216, 230 and 324 were generated (Figure 4.1). 
 
 
Figure 4.1  Mutant MPR4 fragments. Lane 1-5 shows fragment for the F324A, 
F324W, W216A, W230A, W230F mutants. The fragments are 1184 bp each. Lane 
m shows the DNA markers. 
1.0 kb 
1.5 kb 
    m    1     2     3    4    5 
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4.1.2  Cloning of mutant MRP4 fragments into pGEM-T 
The PCR products containing the five mutants (W216A, W230A, W230F, F324A, 
F324W) were cloned into the cloning vector pGEM-T. The clones were digested 
with the appropriate restriction enzyme (EcoRI, EcoRV) to generate the 1184 bp 
insert. Sequencing was then carried out. The sequences of all mutant clones were 
compared with the wild type MRP4 by using the BLAST program. All mutant 
clones were identical to the wild-type MRP4 except for the mutated sites. As 
shown in Figure 4.2, the restriction enzyme digestions demonstrated that the 
digestion products were of the expected size (1184 bp). 
 
 
Figure 4.2 Restriction enzyme (EcoRI, EcoRV) digestion of W216A, W230A, 
W230F, F324A, F324W in pGEM-T vector. Lane 1-5 showed W216A, W230A, 
W230F, F324A, F324W fragment. The 1184 bp band is the insert and the 3000 bp 
band is the pGEM-T vector. Lane 6 shows the DNA markers. 
 
4.1.3 Construction of mutant full-length MRP4 ORFs 
The 1184bp fragments were subcloned in frame back to the MRP4/pcDNA6 
3 kb 
1 kb 
     1   2    3   4    5    6 
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construct to get the recombinant mutant MRP4-pcDNA6 vector. The full-length 
mutant MRP4 ORFs in the pcDNA6 vector were subjected to restriction enzyme 
(EcoRI, XhoI) digestion (Figure 4.3) and sequenced again. The sequence of the 








Figure 4.3  Restriction enzyme (EcoRI, XhoI) digestion of mutant 
MRP4-pcDNA6 constructs. Lane 1-5 shows the mutant clones W216A, W230A, 
W230F, F324A, F324W respectively. The 3695 bp bands were mutant MRP4s, the 
5.1 kb bands were pcDNA6-V5-His vectors. Lane M shows the DNA markers. 
 
 
Figure 4.4  The DNA sequences of mutant MRP4-pcDNA6 constructs. Query 
lines show the published MRP4 cDNA sequence, while Sujct line show mutant 




Query:991   aaagtcattttcaaatcttattaccaatttgagaaagaaggagatttccaagattctgag1050 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sujct:283   aaagtcattttcaaatcttattaccaatttgagaaagaaggagatttccaagattctgag 224 
 
Query: 1051 aagttcctgcctcagggggatgaatttggcttcgTTTttcagtgcaagcaaaatcatcgt 1110 
            ||||||||||||||| ||||||||||||||||||  |||||||||||||||||||||||| 









Query:991   aaagtcattttcaaatcttattaccaatttgagaaagaaggagatttccaagattctgag1050 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sujct:283   aaagtcattttcaaatcttattaccaatttgagaaagaaggagatttccaagattctgag 224 
 
Query: 1051 aagttcctgcctcagggggatgaatttggcttcgTTTttcagtgcaagcaaaatcatcgt 1110 
            ||||||||||||||| ||||||||||||||||||  |||||||||||||||||||||||| 




                                                                         
Query: 732  atcaggtgacagtgttcttacacttcctgtgggcaggaccactgcaggcgatcgcagtga 791 
            |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||| 
Sbjct: 531  atcaggtgacagtgttcttacacttcctgtgggcaggaccactgcaggcgattgcagtga 472 
 
Query: 792  ctgccctactcTGGatggagataggaatatcgtgccttgctgggatggcagttctaatca 851 
            |||||||||||   |||||||||||||||||||||||||||||||||||||||||||||| 





Query: 732  atcaggtgacagtgttcttacacttcctgtgggcaggaccactgcaggcgatcgcagtga 791 
            |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||| 
Sbjct: 531  atcaggtgacagtgttcttacacttcctgtgggcaggaccactgcaggcgattgcagtga 472 
 
Query: 792  ctgccctactcTGGatggagataggaatatcgtgccttgctgggatggcagttctaatca 851 
            ||||||||||||  |||||||||||||||||||||||||||||||||||||||||||||| 





Query: 656  cttagtaacatggccatggggaagacaaccacaggccagatagtcaatctgctgtccaat 715 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 606  cttagtaacatggccatggggaagacaaccacaggccagatagtcaatctgctgtccaat 547 
                                                                         
Query: 716  gatgtgaacaagtttgatcaggtgacagtgttcttacacttcctgTGGgcaggaccactg 775 
            |||||||||||||||||||||||||||||||||||||||||||||   |||||||||||| 
Sbjct: 546  gatgtgaacaagtttgatcaggtgacagtgttcttacacttcctgGCAgcaggaccactg 487 
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4.2 Expression of mutant MRP4 in HepG2 cells 
 
4.2.1  Levels of mutant MRP4 expression in HepG2 cells 
Plasmid constructs carrying certain mutated amino acids were stably transfected 
into HepG2 cells followed by selection with blasticidin. Two control transfections, 
with the wild type MRP4 and the empty pcDNA vector, were also carried out. 
Protein expression level was first analyzed by immunoblotting. MRP4 was cloned 
in frame with a V5 epitope and a polyhistidine sequence at the C-terminal. The 
predicted size of MRP4 (149KD) with the V5 and polyhistidine sequence is 153kD. 
Using an anti-V5 antibody, a protein of about 150kD was detected in both mutant 
and wild type MRP4/HepG2 cells but not in Vector/HepG2 cells. To normalize the 
quantity of MRP4, actin expression was also determined using an anti-actin 
antibody. The expression of the 42kD actin was observed in all cell lines. 
Relatively levels of protein expression were analyzed by densitometric analysis 
and the ratios of wild-type and the mutant MRP4 to actin were calculated. The 
mutant clones with comparable expression levels with the wild-type MRP4 were 











Figure 4.5 Western blot analysis of wild type and mutant MPR4 proteins. Total 
cell lysates were size fractioned using a 8 % polyacrylamide gel. The fractionated 
proteins were transferred to a nitrocellulose membrane, and MRP4 was detected 
by incubation with monoclonal antibody anti-V5 antibody. The numbers in the 
table below the blots referred to the relative expression level. Cells stably 
transfected with wild type MRP4 or empty pcDNA6 vector served as controls. 
A. MRP4 expression of several mutant clones. Relatively levels of protein 
expression were analyzed and the ratio of wild-type and mutant MRP4 was 
calculated.  
B. The mutant clones with the comparable expression level with the wild-type 




   1       2      3      4        5     6 
                Actin                               
 
              MRP4              
 
Lane  1 2 3 4 5 6 
Name Wild type W230A-1 W230A-2 W230F-1 W230F-2 vector 
Ratio(MRP4/Actin) 0.74 0.48 0.71 0.78 0.68  
Ratio(mutant/wild-type)  0.65 0.96 1.05 0.92  
Clone chosen   √ √   
 
              B 
                       1     2    3     4    5     6     7                        
Actin                  
 
MRP4                 
    
Lane       1 2 3 4 5 6 7 
Name Wild type W230A W230F W216A F324A F324W vector 
Ratio(MRP4/ 
Actin) 
0.86 0.79 0.79 0.82 0.84 0.74  
Ratio(mutant/ 
wild-type) 
 0.92 0.92 0.95 0.98 0.86  
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4.2.2 Localization of mutant MRP4 in HepG2 cells 
Immunostaining was carried out to ensure that mutant MRP4 proteins were 
correctly localized to the membrane of the cells. An anti-V5 antibody conjugated 
to FITC was used to stain the cells. Propidium iodide was used to counterstain the 
cells. As shown in Figure 4.6, the wild type and mutant MRP4 proteins were 
present on the cell membrane. 
Figure 4.6  Immunolocalization of expressing wild-type and mutant MRP4s in 
HepG2 cells. MRP4 was detected by immunofluorescence with anti-V5-antibody 
(green signal). Nucleic acids were detected by counterstaining with propidium 





























Wild type MRP4 
 
 
4.3 Functional study of mutant MRP4 
To understand the role of highly conserved amino acids on MRP4 transport ability 
and drug resistance, Trp216 was replaced with non-conserved amino acid Ala, 
Trp230 was replaced with either non-conserved amino acid Ala or the aromatic 
amino acid Phe and Phe324 was replaced with either non-conserved amino acid Ala 
or aromatic amino acid Trp. As shown in Figure 4.5, the levels of expression of 
these proteins were comparable to those of wild-type MRP4. 
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4.3.1  Cytotoxic assay 
MRP4 acts as a plasma membrane drug efflux pump and can confer resistance to 
certain nucleoside analogs (Schuetz et al., 1999; Chen et al., 2001; Adachi et al., 
2002; Lai and Tan, 2002; Wielinga et al., 2002). In this study, the MRP4 
full-length cDNA was stably transfected into human HepG2 cells. Empty pcDNA6 
vector was also stably transfected into HepG2 cells and these were used as the 
controls. The ability to confer resistance to 6-thioguanine (6TG) was then 
examined. As expected, MRP4/HepG2 cells showed a 2.67 fold resistance.  
 
To determine the drug sensitivity of mutant MRP4 protein, cytotoxic assays were 
carried out on stably transfected mutant MRP4/HepG2 cells. Wild-type 
MRP4/HepG2 and empty pcDNA6/HepG2 were used as the positive and negative 
controls respectively. As was observed previously by Lai and Tan, cells 
overexpressing wild-type MRP4 can confer resistance to 6TG (Lai and Tan, 2002).  
 
In this study, we found that the IC50 values of mutant clones F324W, F324A, 
W216A, W2230A and W230F for 6TG were similar to that of cells transfected 
with vector. This indicates that substitution of amino acids at position 324 or 216 
or 230 in the putative first transmembrane segment of MRP4 protein with either 
conserved or non-conserved amino acid residues resulted in the loss of drug 
resistance for 6TG. The IC50 values are shown in Table 4.1. 
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Table 4.1   IC50 values for 6TG. 
After the cells were exposed to 6TG for 48 hours, 20μl of the MTS regent was 
added and cells were incubated at 37ºC for 1 hour. The absorbance at 490nm was 
measured. The IC50 values were calculated as the concentration of each compound 
reducing the number of living cells by 50%. At least five drug concentrations were 
used to calculate the IC50 values. The fold resistance is obtained by the ratio of the 
IC50 of the cells overexpressing wild-type or mutant MRP4 to that of controlled 
vector cells. Each IC50 value represents mean± S.D. of triplicate determinations in 
a single experiment.  
 
                               Cell  Line 
 
 
















Fold 2.67 1.00 1.34 1.16  1.31 1.26 1.34 
 
4.3.2 Export of bimane-glutathione 
 
4.3.2.1  Export of bimane-GS by wild-type MRP4/HepG2 cells 
Monochlorobiman (MCB) enters the cells by simple diffusion and is conjugated 
with glutathione (GSH) to form the fluorescent bimane-glutathione. MCB is 
cell-permeant and does not fluorescence. It is conjugated to GSH by glutathione 
S-transferase to form a cell-impermeant and fluorescent bimane-GS conjugate. 
MCB has been widely used as a fluorescent label for quantifying GSH levels in 
MRP overexpressing cells (Homma et al., 1999). To investigate the changes in the 
mutant MRP4 transport ability of glutathione conjugate, bimane-GS efflux assays 
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were performed on all cell lines (wild-type MRP4/HepG2, Vector/HepG2, mutant 
MRP4/HepG2). MRP4 overexpressing (MRP4/HepG2) cells and vector controls 
(Vector/HepG2) were first used to examine the formation and efflux of the 
fluorescent bimane-GS adduct. Cells were firstly incubated with 100μM MCB at 
10ºC for 1 hour. This was done to avoid active efflux of the bimane-GS. 
Following this, the cells preloaded with MCB were incubated at 37ºC and a 
time-dependent efflux of bimane-GS could be observed. 
 
The amount of bimane-GS present in the incubation buffer of MRP4/HepG2 cells 
increased from 23.0±1.7nmol/mg protein to 44.4±1.8nmol/mg protein over 
period of 15 mins. In contrast, the bimane–GS efflux of Vector/HepG2 increased 
gradually from 14.7±0.8nmol/mg protein to 34.4±3.8nmol/mg protein (Figure 
4.7 B). The efflux of bimane-GS from MRP4/HepG2 cells was rapid and tapered 
off after 10 mins as intracellular bimane-GS levels decreased and became limiting. 
After 15 mins, about 70% of the bimane-GS has been transported out of the cells 
(Figure 4.7 A). At all time point, export of bimane-GS from MRP4/HepG2 cells 
was significantly higher than that from Vector/HepG2 cells. Since the total 
synthesis of bimane-GS in MRP4/HepG2 cells (64.0±0.8nmol/mg protein) and 
Vector/HepG2 cells (62.4±3.4nmol/mg protein) was comparable, the higher 




Figure 4.7  Efflux of bimane-GS from Vector/HepG2 cells and MRP4/HepG2 
cells 
Cells were preincubated at 10ºC with medium containing 100 μM of MCB. The 
medium was removed and replaced with HBSS containing 5.6mM glucose and 
incubated at 37ºC.  
A  Percent bimane-GS efflux at each time point (5’, 10’, 15’). The percent efflux 
was calculated by taking the ratio of the amount of bimane-GS in the incubation 
buffer to that of the total bimane-GS (sum of bimane-GS in incubation buffer and 
cell lysate) and multiplying by 100%. 
B  Bimane-GS exported into the incubation buffer. 
C  Intracellular bimane-GS over a period of 15 mins.  
All points for the MRP4/HepG2 cells except that at 0min were significantly 
different from that of Vector/HepG2 cells (Student’s test, p<0.05). Each point and 
bar represents mean± S.D. of triplicate determinations in a single experiment. The 
solid line shows the values for MRP4/HepG2 cells and the broken line shows the 


























































































4.3.2.2  Export of bimane-GS by mutant MRP4/HepG2 cells 
A time curve of bimane-GS efflux was carried out in mutant clones as described in 
section 3.4.3. Assays with cells transfected with the wild–type MRP4 or the empty 
pcDNA6 vector were also performed at the same time. These served as the 
positive and negative control respectively. As shown in Table 4.2, the amount of 
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bimane-GS synthesis was similar to that of wild-type MRP4 and vector transfected 
controls. Analysis of bimane-GS transport by all clones with mutant sites showed 
that bimane-GS efflux was greatly reduced and were similar to that of the 
vector-transfected clones (Figure 4.8). These indicated that substitution of Trp216 
with Ala, Trp230 with Ala or Phe and Phe324 with Ala or Trp led to the complete 
loss of MRP4-mediated efflux of bimane-GS.  
 
Table 4.2  Bimane-GS synthesis in the cells overexpressing wild-type or mutant 
MRP4 over a 15-min period. Cells were preincubated at 10ºC with 1ml DMEM 
per well containing 100μM MCB for 1 hour. The medium was removed and 
replaced with HBSS containing 5.6 mM glucose and was incubated at 37ºC. 
Bimane-GS exported into the incubation buffer and intracellular bimane-GS were 
measured over a period of 15 mins. The total bimane-GS synthesis is the sum of 
bimane-GS in incubation buffer and cell lysate. Each value represents mean ± S.D. 
of triplicate determinations in a single experiment. All results from the mutant 
clones were comparable to that of wild-type MRP4 and vector transfected cells. 
 
Cell line Bimane-GS synthesis  










Figure 4.8  Efflux of bimane-GS conjugate by cells expressing wild-type or 
mutant MRP4.Cells stably transfected with the vector were also include. Cells 
were incubated with 1 ml DMEM containing 100μM MCB at 10ºC for 1 hour. 
Bimane-GS exported into the incubation buffer and intracellular bimane-GS was 
measured over a 15-min time course. The percent efflux was calculated by taking 
the ratio of the amount of bimane-GS in the incubation buffer to that of the total 
bimane-GS (sum of bimane-GS in incubation buffer and cell lysate) and 
multiplying by 100%. Percent efflux from mutant MRP4 clones, F324W, F324A, 
W230A, W230F, W216A are shown in figure A-E respectively. Efflux from 
wild-type MRP4 and vector transfected cells are included in every figure. All 
points for wild-type MRP4/HepG2 cells with the exception of that at 0 min were 
significantly different from the observed for mutant MRP4/HepG2 and 
Vector/HepG2 cells (student’s t-test, p<0.05). Each point and bar represents mean 
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4.4  Screening for inhibitors of MRP4 
 
4.4.1  Effects of oxopurine and azapurine compounds on bimane-GS export 
Various compounds containing the purine (eg 6-MP, PMEA, 6TG) and azapurine 
(sildenafil) templates have inhibitory activities against MRPs (Schuetz et al., 1999; 
Chen et al., 2001; Adachi et al., 2002; Lai and Tan, 2002; Wielinga et al., 2002). 
These earlier works prompted us to make variations at the different sites on the 
purine template and study their inhibitory activities. 6-oxopurine derivatives are 
similar in structure to 6TG with the exception of an O instead of S at position 6. A 
screen of seventeen 6-oxopurine derivatives was carried out. Initial experiments 
were conducted with 100μM of the derivatives. Of the 17 derivatives screened, 
only two were able to influence the bimane-GS transport ability of MRP4. The 
presence of 25μM of compound FH-15 led to significant reduction in 
MRP4-mediated transport (Table 4.3). The efflux was reduced from 7.7nmol/mg 
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protein to 2.9nmol/mg protein. At this concentration, there was no reduction in 
efflux by the control Vector/HepG2 cells. At the higher concentrations of 50μM 
and 100μM, there were as expected significant inhibition of MRP4-mediated 
transport but at these concentration, compound FH-15 also significantly reduced 
the efflux in the control Vector/HepG2 cells. The effects of compound FH-15 were 
specific on the efflux process as there were no differences in the total bimane-GS 
synthesis between cells that were exposed to compound FH-15 and those that were 
not. Significant inhibition of MRP4-mediated transport was also observed in the 
presence of 25μM of compound FH-16 although the degree of inhibition was 
much less than that observed for compound FH-15 (Table 4.3). As was observed 
for compound FH-15, compound FH-16 did not affect the total bimane-GS 
synthesis indicating that once again the effect was on the efflux process. 
 
Another series of synthetic compounds containing the azapurine template was also 
examined to see if these compounds can influence the MRP4-mediated transport 
of bimane-GS (Table 4.4). A total of 22 azapurine compounds were tested. Of 
these, two were found to affect the efflux of bimane-GS. Bimane-GS efflux from 
MRP4/HepG2 was reduced from 22.5nmol/mg protein to 18.7nmol/mg protein in 
the presence of 125μM of compound MSR37. Similar reduction in efflux was 
also observed at 150μM. At concentrations up to 150μM, compound MSR37 
had no effect on total bimane-GS synthesis. It also did not affect the efflux of 
bimane-GS from control Vector/HepG2 cells. The second azapurine compound 
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which was effective was compound MSR15. Efflux of bimane-GS was reduced 
from 23.7nmol/mg protein to 19.9nmol/mg protein in the presence of 125μM of 
compound MSR15. At this concentration, there was no effect on the efflux from 
the Vector/HepG2 cells. There was also no effect on total bimane-GS synthesis. In 
contrast, 150μM of compound MSR15 led to significant reduction efflux from the 
control Vector/HepG2 cells. 
 
Table 4.3  Effects of 6-oxopurine derivatives (compounds FH-15, FH-16) on 
bimane-GS efflux. 
Cells were incubated in 1 ml DMEM containing 100μM MCB at 10ºC for 1 hour 
together with compound FH-15 or FH-16 at 25, 50 or100μM. The medium was 
then removed and efflux was carried out at 37ºC in HBSS buffer containing 
5.6mM glucose for 5 mins. The difference between the efflux from Vector/HepG2 
and those from MRP4/HepG2 cells represents the efflux mediate by MRP4. Data 
are expressed as mean±S.D. from three independent experiments. *compared 
























Concentration of  Total bimane-GS           Bimane        Bimane       Efflux 
compounds       Synthesized in            efflux from     efflux from  mediated by 
(μm)         vector/Hepg2(top)          vector/Hepg2    MRP4/Hepg2   MRP4 
               And MRP4/Hepg2          cells           cells         (nmol/mg 
(bottom)                 (nmol/mg       (nmol/mg     protein) 
                (nmol/mg protein)          protein)        protein) 
Compound FH-15 
 
0              48.2±1.1/             14.6±0.7      22.3±1.0       7.7±0.5 
               48.5±1.7 
 
25             50.2±3.5/              14.3±1.0      17.1±0.6*      2.9±0.8* 
               48.3±3.4 (37%)* 
 
50             50.0±3.7/            11.8±1.3*     16.0±1.4*     4.3±1.3* 
               49.5±2.5                                            (55%)* 
 
100            50.6±2.2/             11.2±0.2*      15.6±1.0*      4.4±1.0* 




0              50.5±2.4/            15.6±0.6       23.3±0.9       7.7±0.4 
               49.2±2.8 
 
25             49.7±2.4/             14.3±0.8       19.7±0.9*      5.4±0.9* 
               50.0±3.8                                            (70%)* 
 
50             51.0±2.0 /             13.1±1.1*     19.2±0.6*       6.1±0.7 
               50.2±1.8                                             (78%) 
 
100            51.0±3.3/              11.6±0.7*     18.2±1.7*       6.6±1.0 












Table 4.4  Effects of azapurine derivatives (compounds MSR15, MSR37) on 
bimane-GS efflux. 
Cells were incubated in 1 ml DMEM containing 100μM MCB at 10ºC for 1 hour 
together with compound MSR15 or MSR37 at 0 to 150μM. The medium was 
then removed and efflux was carried out at 37ºC in HBSS buffer containing 5.6 
mM glucose for 5 mins. The difference between the efflux from Vector/HepG2 and 
those from MRP4/HepG2 cells represents the efflux mediate by MRP4. Data are 
expressed as mean±S.D. from three independent experiments. *compared with 






































Concentration of  Total bimane-GS           Bimane        Bimane       Efflux 
compound       Synthesized in           efflux from     efflux from    mediated by 
(μm)           vector/Hepg2(top)       vector/Hepg2    MRP4/Hepg2   MRP4 
               And MRP4/Hepg2          cells          cells         (nmol/mg 
(bottom)                 (nmol/mg       (nmol/mg     protein) 
                (nmol/mg protein)          protein)        protein) 
Compound MSR37 
0              56.0±2.9/              14.8±0.8       22.5±0.2    7.7±0.9 
               57.4±2.5 
 
25             57.7±3.5/              15.4±1.0       22.0±0.4    6.6±0.9 
               59.5±1.3 (86%) 
 
50             56.6±1.1/              15.3±0.4      21.5±0.9   6.2±1.2 
               57.5±2.1                                           (81%) 
 
100            57.1±4.7/              15.2±1.8       21.3±0.9    6.1±1.3 
               60.7±1.9                                           (79%) 
 
125            56.4±2.5/              14.3±1.3       18.7±0.7*   4.4±1.1* 
               57.2±1.9                                           (58%)* 
 
150            59.2±4.6/              13.8±1.5       18.2±0.9*   4.4±1.2* 
               58.4±1.1                                           (58%)* 
 
Compound MSR15 
0              57.1±3.4 /            16.2±1.3        23.7±0.5    7.5±1.5 
               56.8±1.2 
 
25             57.6±1.7/              17.5±0.9       22.9±0.3     5.4±0.8 
               55.3±1.0                                            (72%) 
 
50             54.2±0.4/              16.8±0.3       22.0±1.1     5.1±0.8 
               53.5±2.5                                            (68%)* 
 
100            57.6±1.4/              16.1±0.7       20.6±0.3*    4.5±0.6* 
               58.9±2.1                                            (60%)* 
 
125            59.4±4.6/              14.4±1.0       19.9±0.6*    5.5±0.6 
               57.9±1.4                                            (74%)* 
 
150            56.7±1.4/              13.5±1.8*     18.3±1.5*     4.8±0.3 
               58.1±2.2                                            (64%)* 
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4.4.2  Effects of oxopurine and azapurine compounds on 6TG resistance 
The two oxopurines, FH-15 and FH-16 and the two azapurine, MSR37 and 
MSR15 were used for further investigations on whether these compounds can 
affect resistance to 6TG. Before carrying out the actual assay, MRP4/HepG2 cells 
and Vector/HepG2 cells were treated with various concentrations of these 
compounds for 48 hours to examine the effects on cell proliferation. As shown in 
Table 4.5, 10μM of compound FH-15 and 25μM of the other three compounds 
did not affect cell growth and proliferation. Thus these concentrations were used 
for the next series of experiments. All four compounds can reverse the 
MRP4-mediated resistance to 6TG (Table 4.6). The IC50 values were significantly 
reduced in the presence of all 4 compounds. In addition, for compound MSR37, 
MSR15, the reversal was complete and the IC50 values were similar to that for 
Vector/HepG2 cells. 
 
Table 4.5  Viability of MRP4/HepG2 cells (M) and Vector/HepG2 cells(V). 
The cells were treated with FH-15, FH-16, MSR37 or MSR 15.  
ND= not determined. 
Drug 
concentration 
0 (μm) 10(μm) 25 (μm) 50 (μm) 100 (μm) 
FH-15   M  
        V 
 
FH-16   M 
        V 
 
MSR37  M 
        V 
 
MSR15  M 




























































Table 4.6  IC50 for 6TG in the presence of oxopurine and azapurine derivatives. 
The cells were exposed to 6TG together with compound FH-15 (10μm) or  
compound FH-16 (25μm) or compound MSR37 (25μm) or compound MSR15 
(25μm) for 48 hours. 20μL of MTS reagent was added and cells were incubated 
at 37ºC for 1 hour. The absorbance at 490nm was measured. IC50 is the 
concentration at which cell growth is inhibited by 50%. At least five drug 
concentrations were used to determine IC50. Each concentration was carried out in 
triplicate. Data are expressed as mean±S.D.from three independent experiments. 
*compared with the corresponding untreated cells, p<0.05, ANOVA analysis. 
 
Compound                      IC50  (μM) 
                    MRP4/HepG2        Vector/HepG2          Fold resistance 
 
Compound FH-15      18.5±0.3*        13.0±1.1            1.33 
(10μM) 
 
Compound FH-16      29.4±0.9*        15.3±1.0            2.12 
(25μM) 
 
Compound MSR37     12.2±0.5*        10.7±0.6            0.88 
(25μM) 
 
Compound MSR15     14.9±0.6*        12.3±1.4            1.07 
(25μM) 
 











5   Discussion 
 
5.1  Effects of purine analogs on MRP4-mediated transport of 
glutathione-conjugate 
Our study was carried out to further characterize the transport ability of MRP4. 
Early studies had demonstrated that MRP1 is a lipophilic anion transporter capable 
of transporting glutathione conjugates, such as LTC4 and DNP-SG (Jedlitschky et 
al., 1994; 1996). Previous studies had shown that MRP4 has the facility for 
mediating the transport of glucuronides such as E217ßG (Chen et al., 2001; Van 
Aubel et al., 2002) providing evidence that MRP4 may indeed facilitate the 
transport of conjugated molecules. Zelcer et al had observed that estradiol 3, 
17-disulphate and taurolithocholate 3-sulphate could competitively inhibit the 
MRP4 transport of E217ßG (Zelcer et al., 2003), while, Chen et al, van Aubel et al 
showed that glucuronide and glutathione conjugates can inhibit MRP4-mediated 
transport of methotrexate (Chen et al., 2002; van Aubel et al., 2002). 
 
In our study, we use MRP4 overexpressing cell to examine the formation and 
efflux of the fluorescent bimane-GS adducts. Primary cell cultures were not used 
as the preparation of primary cells is labor intensive. In addition, primary cells can 
only be maintained in vitro for a limited period of time. HepG2 cells were from 
human hepatocellular liver carcinoma cells. MRP4 mRNA could no be detected in 
HepG2 cells which suggested that this gene is expressed in HepG2 cells at a very 
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low level (Kool et al., 1997), so we choose HepG2 cells to further study the 
function of MRP4. Similar to previous observations in our group (Bai et al., 2004), 
the data in this study showed that MRP4 indeed can facilitate the efflux of 
bimane-glutathione. The efflux of bimane-GS from MRP4/HepG2 cells was rapid 
and tapered off after 10 mins as intracellular bimane-GS levels decreased and 
became limited. After 15 mins, about 70% of the bimane-GS has been transported 
out of the cells. 
 
Our group had also previously showed that 6TG is capable of inhibiting the 
MRP4-mediated efflux of bimane-GS (Bai et al., 2004). In this study, two series of 
synthetic compounds containing either the oxo-purine or azapurine template were 
examined for their ability to inhibit bimane-GS transport. Four of the compounds, 
namely, FH-15, FH-16, MSR-37 and MSR-15 were all able to reduce the 
MRP4-mediated efflux of bimane-GS. This inhibition was solely on the efflux as 
the synthesis of bimane-GS was not affected by the compounds. A comparison of 
the effectiveness of these synthetic purine or azapurine with that of 6TG is shown 
in table 5.1. The concentrations shown are the highest tested without significant 
effects on the efflux from similarly treated Vector/HepG2 cells. It is evident that 
FH-15 is the best inhibitor (being effective at 25 μM) and MSR37 has inhibitory 




Table 5.1  Effects of inhibitors on MRP4-mediated efflux of bimane-GS. 
Data for 6TG was published by Bai et al., 2004. *compared with export in the 
absent of an inhibitor. p<0.05, ANOVA analysis. 
Inhibitor Percent of control (%) 
None  100 
100μM 6TG 56±9* 
25μM FH-15 37±9* 
25μM FH-16 70±14* 
100μM MSR15 60±14* 
125μMMSR37 58±18* 
 
Oxo-purines and azapruines with no substitutions at the C2 or N9 positions did not 
have any inhibitory activity. A comparison of the structures of the effective 
compounds showed that the difference between the effective and non-effective 
ones may lie on the substitutions present at position 9 and position 2 (Figure 5.1). 
For example, FH-16 has an isobutyl on the 9 position and is active, while FH-14 
has the same structure except for an aromatic ring at the 9 position and it is 
inactive. The activity of FH-16 may be because the isobutyl chain is much smaller 
than the aromatic ring and this may allow it to bind to or interact with MRP4 more 
effectively. A short side chain is indeed present at the N9 position in all the purine 
analogs that were capable of inhibiting bimane-GS efflux in this study (Figure 5.1) 
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FH-15             FH-16                FH-14 














   
MSR15                             MSR37 
Figure 5.1   Structures of some of the synthetic compounds. Compounds FH-15, 
FH-16 and FH-14 contain the oxo-purine template, while compounds MSR37 and 
MSR15 contain the azapurine template. 
 
5.2  Resistance to nucleoside analogs 
Nucleoside analogs are important components of both anticancer and antiviral 
therapies. MRP4 is unique among the MRP family members in that it can confer 
resistance to methotrexate as well as 6-MP (Lee et al., 2000; Chen et al., 2001; 
Lai and Tan, 2002; Wielinga et al., 2002). By carrying out the MTS assay, we 
confirmed that cells overexpressing MRP4 can confer resistance to 6TG. The IC50 
value of 6TG from MRP4 overexpressing cells is 2.67 fold higher than that of 
control cells indicating that MRP4 plays a role in the resistance to 6TG. This is 
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inline with the observations that MRP4 and MRP5 can confer resistance to 
nucleoside analogs such as PMEA, AZT, GCV, 6-MP and 6TG (Schuetz et al., 
1999; Lee et al., 2000; Wijnholds et al., 2000; Adachi et al., 2002; Wielinga et al., 
2002).Wielinga et al had identified that MRP4 transfected human embryonic 
kidney cells could export the thiopurine metabolites 6-MP and 6TG (Wielinga et 
al., 2002). 6TG is a member of a group of chemotherapy drugs known as 
anti-metabolites. It has been shown that 6TG exhibits a delayed cytotoxic activity, 
halting the cell cycle in the G2 phase after one round of replication. Types of 
damage caused by the presence of 6TG include single-and double- strand DNA 
breaks, cross-linking to protein and DNA, sister chromatid exchange events, and 
large-scale chromosomal damage (Maybaum et al., 1983). 6TG is one of the key 
drugs used in the treatment of childhood leukemia. MRP4-overexpressing cells 
mediated resistance to the cytotoxic effects of 6TG may explain some 
unsuccessful chemotherapies of acute leukemia. 
 
Given the fact that MRP4 has the ability to mediate resistance to nucleoside 
analogs (Schuetz et al., 1999; Chen et al., 2001; Adachi et al., 2002; Lai and Tan, 
2002), and also to transport the phosphyorylated metabolites of mercaptopurines 
(Schuetz et al., 1999; Wielinga et al., 2002), it is highly possible that the 
expression of MRP4 may play a role in the pharmacokinetics of resistance to 
nucleoside analogs. Thus one of the aims of this study was to examine if it were 
possible to reverse the MRP4 mediated resistance to 6TG. The approach used here 
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was to use a series of novel purine analogs which are not cytotoxic to the cells. 
Given the fact that four of the synthetic purine analogs were active in inhibiting 
MRP4 mediated bimane-GS efflux, the effects of these analogs on resistance to 
6TG were also investigated. As shown in table 4.6, all the compounds, namely 
FH-15, FH-16, MSR37 and MSR15 were all able to reduce the IC50 of 6TG. With 
the exception of FH16, the other compounds were able to reduce the IC50 to that of 
the controlled cells. The concentrations used to achieve this reversal of resistance 
ranged from 10μM to 25μM. At these concentrations, the compounds had no 
adverse effects on cell proliferation and viability. It is also obvious that the 
synthetic purine analog inhibitors did not affect the uptake or metabolism of 6TG 
as the IC50 values in the control Vector/HepG2 cells were not affected by the 
presence of these analogs. It is indeed promising to observe that it is possible to 
reverse resistance to 6TG by targeting MRP4. 
 
5.3 Mutational analysis of MRP4 function 
Most of the multidrug resistance proteins of clinical importance are ATP-binding 
cassette transporter that confers resistance to a brand spectrum of drugs in tumor 
cells while functioning as primary active transporters of organic anions in normal 
cells. Factors governing the substrate specificity of the MRP-related transporters 
are complex, as can be expected for any relatively large membrane protein that 
recognizes such a variety of different substrates. The physical characteristics of the 
substrate such as its hydrophobicity, aromaticity, and charge, as well as certain 
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aspects of its chemical structure may influence the interaction between the MRP 
and substrate.  
 
Structure/function studies have only recently begun to identify domains and 
individual amino acid residues in MRP that are involved in determining substrate 
specificity. The best characterized protein in the MRP family is MRP1. To date, a 
number of conserved and non-conserved amino acids in different regions of MRP1 
have been shown to affect the substrate specificity and transport efficiency of this 
protein. These studies have shown that mutation of individual aromatic, polar, and 
charged amino acids in each of the three MSDs can affect the recognition and 
transport of one or several substrates in different ways. One of the amino acids is a 
highly conserved tryptophan at position 1246. This residue is located at the 
membrane-cytosol interface of the last transmembrane segment (TM17). The 
studies indicated that this amino acid was critical for the binding and transport of 
some of MRP1 substrates and inhibitors. Replacement of the tryptophan with 
cysteine at 1246 in MRP1 led to the loss of E217ßG transport, as well as the loss of 
resistance to the vinca alkaloid, vincristine and the ability to bind glucuronide 
conjugates (Ito et al., 2001a). Substitutions of the analogous Trp residues in TM17 
of MRP2 and MRP3 (Trp1254 and Trp1242 respectively) have been shown to 
selectively affect the substrate specificity of these transporters. The data 
demonstrated that mutant MRP2-Trp1254 is important for LTC4 transport and is also 
essential for the ability of MRP2 to transport MTX (Ito et al., 2001 b). Similarly, 
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the mutant Trp analogues of MRP3 significantly alter the substrate specificity of 
MRP3 but did not affect bile salt binding and transport (Oleschuk et al., 2003). 
 
One approach toward understanding the molecular details of the transport 
mechanism of MRP4 is to identify the amino acid residues critical for its activity 
by functional analysis of MRP4 mutants created by site-directed mutagenesis. 
Previous studies have shown the importance of Trp residues contribute to the 
transport activity and substrate specificity of the MRP1, MRP2 and MRP3. Trp 
residues located in transmembrane domains are particularly important, since 
labeling studies with photoactive drug analogues suggest that these regions 
contribute to the substrate-binding sites (Safa et al., 1989; Beck et al., 1992; 
Konno et al., 2003). These residues are located in a position that could allow them 
to contribute to the optimal packing of TM helices for substrate translocation as 
well as having the potential to interact directly with at least some of the many 
substrates of the transporter (Strandberg et al., 2002). In addition, MRP1 has a 
usually high frequency of trytophan residues (Koike et al., 2002). MRP4 too has a 
high frequency of 1.8% compared to 1.2% for all proteins (Wallace et al., 1999). 
Based on these considerations, the mutant W216A-MRP4, W230A-MRP4, 
W230F-MRP4, F324A-MRP4 and F324W-MRP4 were generated. As shown in 
figure 5.2, the W216, W230 and F324 of MRP4 are analogous to Trp445, Trp459 and 
Trp553 in MRP1. Topology prediction using TMAP has shown that W216 and 
W230 are located in TM3 while F324 is located in TM5 in MSD1 similar to the 
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localization of the analogous Trp residues in MRP1 (Lee et al., 1998). The goal of 
this study was to determine whether these conserved aromatic amino acids located 
within the predicted transmembrane domain are important for transport ability and 
drug resistance. Mutated MRP4 cDNA were constructed and these were 
successfully expressed in stably transfected HepG2 cells. For all these mutants, 
western blot analysis was carried out to check the expression levels of the proteins. 
The blots showed that the expression levels were similar to that of the wild-type 
MRP4 (Figure 4.5), indicating that none of the mutants had a major effect on the 
expression levels of the protein. The results of immunostaining indicated that all 
these mutants were correctly localized on the plasma membrane in the stable 
transfectants (Figure 4.6). These results indicated that these mutants did not 
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     MSD2       MSD1 
W230 
W459 
      MSD1      MSD2 
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MRP1. 
Topology prediction using TMAP has shown that W216 and W230 are located in 
TM3 while F324 is located in TM5 in MSD1 similar to the localization of the 
analogous Trp residues in MRP1. 
 
MCB efflux assay was carried out to further characterize the transport function of 
MRP4. In this study, MCB was used to determine if cells overexpressing MRP4 
was able to transport bimane-GS. MCB is non-fluorescent by itself, while it is can 
form a stable fluorescent adduct with GSH, preferentially over other thiols. The 
formation of bimane-GS is catalyzed by glutathione-S-transferase (GST). Our 
results indicated that transport of bimane-GS by all mutant MRP4s (W216A, 
W230A, F324A, W230F, F324W) were not comparable to that of the wild-type 
MRP4/HepG2 cells. Furthermore, the cytotoxic assays indicated that the 
substitution of W216, W230 and F324 with either non-conserved (Ala) or 
conserved (Trp or Phe) amino acid residues resulted in the loss of resistance to 
6-thioguanine.  
 
From figure 1.5, we can conclude that the tryptophan residue is extremely well 
conserved among MRP (ABCC) subfamily members. Trp residues with their large 
indole (benzopyrrole) side chains have the greatest steric bulk of all the amino 
acids. Thus all Trp substitutions examined in our study resulted in mutant MRP4 
proteins with less steric bulk than that is found in the wild-type protein. Alanine 
was chosen as a replacement, since it is a small neutral amino acid that would 
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preserve the α–helical nature of the transmembrane segments, while phenylalanine 
was used as a substitution, since it has an aromatic side chain, similar to that of 
trytophan. Based on the same reasons, the phenylalanine residue was substituted 
with alanine or tryptophan.  
 
The non-conserved replacement of Trp or Phe with Ala at 216, 230, 324 in TM3 
and TM5 respectively abrogated transport of bimane-GS and reversed resistance to 
6-TG indicating that the aromatic properties of the residue are critical for retaining 
transport activity and specificity. Replacement of aromatic amino acids Trp or Phe 
with Ala can cause cavity-creating mutations, since the spatial volume occupied by 
the Ala side chain is a great deal less than that occupied by the side chains of Trp 
or Phe. In addition, the Trp residues often tend to cluster at the interface between 
the polar head group region and the hydrophobic interior of the lipid bilayer, the 
substitution of Ala, a nonaromatic nonpolar residue with a minimal side chain 
volume can significantly reduce the efficiency of proper membrane anchoring of 
the protein. This can alter the positioning and effective hydrophobic length of the 
TM helix and thus disrupt the appropriate packing of TM segments necessary for 
substrate recognition and transport. 
  
Koike et al found the W445F-MRP1 mutant (the analogue of W216F-MRP4) was 
able to recover some of the wild type MRP4 transport activity compared to the 
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Ala-substituted mutant (Koike et al., 2002). However, this study showed that 
W216F-MRP4 mutant displayed the similar phenotype as that of the 
Ala-substituted mutant. Our studies implied that the tertiary interactions of these 
aromatic residues may important for the bimane-GS transport. The W230F mutant 
was also unable to transport bimane-GS and to confer drug resistance, indicating 
that the aromaticity of the amino acid is a critical determinant for substrate binding 
and transport ability. 
Taken together, these findings indicate that the aromatic amino acids at 
transmembrane domain of MRP4 protein may function to either maintain or form 
part of a substrate-binding pocket, and it may interact directly with the metabolites 













6  Conclusion 
 
To further characterize the MRP4 substrate specificity and transport ability, we 
used the stably transfected MRP4/HepG2 cells. This study provided evidence that 
MRP4 can indeed facilitate the ATP-dependent efflux of the glutathione conjugate, 
bimane-GS. This study also confirmed that MRP4 acts as a plasma membrane drug 
efflux pump and is able to confer resistance to the nucleoside analog, 6TG. As 
expected, MRP4/HepG2 cells showed a 2.67 fold increase in resistance to 6TG. 
  
In addition, we examined whether some synthetic purine compounds can affect the 
MRP4-mediated transport ability and drug resistance. The compounds used for 
screening contain either the oxo-purine or the azapurine template. The data 
indicated that several of them could inhibit the bimane-GS efflux and reverse the 
resistance to 6TG. However what is the important determinant of these compounds 
that influence the MRP4-mediated transport and drug resistance remains largely 
unknown.  Additional molecular and pharmacological studies are needed to 
continue to provide more information on the structural features that determine how 
these compounds influence the MRP4-mediated glutathione conjugate and drug 
resistance. 
 
Furthermore, the contributions of aromatic amino acid residues Trp216, Trp230 in 
TM3 and Phe324 in TM5 of MSD1 to MRP4 functions were examined. Mutation to 
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any of these sites led to the loss of the ability to transport bimane-glutathione and 
to confer resistance to 6TG. This suggests that aromatic amino acid residues Trp216, 
Trp230 in TM3 and Phe324 in TM5 of MSD1 play important roles in 
MRP4-mediated substrate recognition and transport ability. In this study, 
bimane-glutathione was only used as substrate for transport activity of MRP4. 
Further studies with other MRP4 substrates as glucuronate and sulfate conjugates 
are also needed to reveal whether these aromatic acids can influence the MRP4 
transport ability and drug resistance. 
 
Due to the limited mutated residues, it is difficult to determine structural and 
functional mechanism of the transport and drug resistance mediated by MRP4. 
Mutational analysis of other highly conserved residues needs to be done. This will 
reveal the exact distribution and bonding interactions of the Trp, Phe residues of 
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